Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11361047,area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)),Mean area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)) was 25.6 microg x h/mL in younger subjects and 36.0 microg x h/mL in older subjects (p < 0.001).,Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361047/),[h·μg] / [ml],25.6,987,DB00996,Gabapentin
,11361047,area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)),Mean area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)) was 25.6 microg x h/mL in younger subjects and 36.0 microg x h/mL in older subjects (p < 0.001).,Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361047/),[h·μg] / [ml],36.0,988,DB00996,Gabapentin
,11361047,peak plasma concentrations (Cmax),Corresponding mean peak plasma concentrations (Cmax) were 3.74 and 4.52 microg/ml (p < 0.05).,Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361047/),[μg] / [ml],3.74,989,DB00996,Gabapentin
,11361047,peak plasma concentrations (Cmax),Corresponding mean peak plasma concentrations (Cmax) were 3.74 and 4.52 microg/ml (p < 0.05).,Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361047/),[μg] / [ml],4.52,990,DB00996,Gabapentin
,11361047,Oral clearance,"Oral clearance (normalized for body weight) was 7.40 and 4.41 mL/min/kg in younger subjects and older subjects, respectively (p < 0.001).",Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361047/),[ml] / [kg·min],7.40,991,DB00996,Gabapentin
,11361047,Oral clearance,"Oral clearance (normalized for body weight) was 7.40 and 4.41 mL/min/kg in younger subjects and older subjects, respectively (p < 0.001).",Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361047/),[ml] / [kg·min],4.41,992,DB00996,Gabapentin
,20840393,Terminal elimination half-life (t(1/2γ) ),Terminal elimination half-life (t(1/2γ) ) was 8.5 (7.1-13.3) h.,Pharmacokinetic profile and behavioral effects of gabapentin in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840393/),h,8.5,3212,DB00996,Gabapentin
,20840393,terminal elimination half-life (),After p.o. gabapentin terminal elimination half-life () was 7.7 (6.7-11.9) h.,Pharmacokinetic profile and behavioral effects of gabapentin in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840393/),h,7.7,3213,DB00996,Gabapentin
,20840393,oral bioavailability,The mean oral bioavailability of gabapentin (± SD) was 16.2 ± 2.8% indicating relatively poor absorption of gabapentin following oral administration in horses.,Pharmacokinetic profile and behavioral effects of gabapentin in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840393/),%,16.2,3214,DB00996,Gabapentin
,22775354,relative bioavailability,"The relative bioavailability compared with the 600 mg dose was 86-88% for the 1200 mg/day doses, 75% for the 1800 mg/day dose, 84% for the 2400 mg/day dose, and 73% for the 3000 mg/day dose.",Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775354/),%,86-88,8061,DB00996,Gabapentin
,22775354,relative bioavailability,"The relative bioavailability compared with the 600 mg dose was 86-88% for the 1200 mg/day doses, 75% for the 1800 mg/day dose, 84% for the 2400 mg/day dose, and 73% for the 3000 mg/day dose.",Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775354/),%,75,8062,DB00996,Gabapentin
,22775354,relative bioavailability,"The relative bioavailability compared with the 600 mg dose was 86-88% for the 1200 mg/day doses, 75% for the 1800 mg/day dose, 84% for the 2400 mg/day dose, and 73% for the 3000 mg/day dose.",Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775354/),%,84,8063,DB00996,Gabapentin
,22775354,relative bioavailability,"The relative bioavailability compared with the 600 mg dose was 86-88% for the 1200 mg/day doses, 75% for the 1800 mg/day dose, 84% for the 2400 mg/day dose, and 73% for the 3000 mg/day dose.",Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775354/),%,73,8064,DB00996,Gabapentin
,22775354,t(max),"The values of t(max) were not different between the various doses, with the median t(max) values relative to the most recent dose ranging from 6 to 8 hours for all dose levels.",Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22775354/),h,6 to 8,8065,DB00996,Gabapentin
,33924091,IC50,"Compounds 19 (4-NO2 derivative) and 20 (4-SO2NH2 derivative), with an IC50 value of 8.4 and 7.6 nM, were found most active, respectively.",Analgesic and Anticancer Activity of Benzoxazole Clubbed 2-Pyrrolidinones as Novel Inhibitors of Monoacylglycerol Lipase. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33924091/),nM,8.4,8239,DB00996,Gabapentin
,33924091,IC50,"Compounds 19 (4-NO2 derivative) and 20 (4-SO2NH2 derivative), with an IC50 value of 8.4 and 7.6 nM, were found most active, respectively.",Analgesic and Anticancer Activity of Benzoxazole Clubbed 2-Pyrrolidinones as Novel Inhibitors of Monoacylglycerol Lipase. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33924091/),nM,7.6,8240,DB00996,Gabapentin
above,33924091,IC50,"Both of them showed micromolar potency (IC50 value above 50 µM) against a close analogue, fatty acid amide hydrolase (FAAH), therefore considered as selective inhibitors of MAGL.",Analgesic and Anticancer Activity of Benzoxazole Clubbed 2-Pyrrolidinones as Novel Inhibitors of Monoacylglycerol Lipase. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33924091/),μM,50,8241,DB00996,Gabapentin
,24168107,renal clearance (CLR ),"A statistically significant but modest increase in the renal clearance (CLR ) of gabapentin occurred after intake of the mushroom diet (91.1 ± 25.1 vs. 76.9 ± 20.6 ml min(-1) , P = 0.031).",Effect of mushroom diet on pharmacokinetics of gabapentin in healthy Chinese subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168107/),[ml] / [min],91.1,10227,DB00996,Gabapentin
,24168107,renal clearance (CLR ),"A statistically significant but modest increase in the renal clearance (CLR ) of gabapentin occurred after intake of the mushroom diet (91.1 ± 25.1 vs. 76.9 ± 20.6 ml min(-1) , P = 0.031).",Effect of mushroom diet on pharmacokinetics of gabapentin in healthy Chinese subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168107/),[ml] / [min],76.9,10228,DB00996,Gabapentin
,30192429,absorption rate constant,"The absorption rate constant, volume of distribution, and clearance estimated were 0.44 h-1 , 86 L, and 17.3 × (estimated glomerular filtration ratio/89.58)1.04 L/h, respectively.",Pharmacogenetics-based population pharmacokinetic analysis of gabapentin in patients with chronic pain: Effect of OCT2 and OCTN1 gene polymorphisms. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30192429/),1/[h],0.44,12873,DB00996,Gabapentin
,30192429,volume of distribution,"The absorption rate constant, volume of distribution, and clearance estimated were 0.44 h-1 , 86 L, and 17.3 × (estimated glomerular filtration ratio/89.58)1.04 L/h, respectively.",Pharmacogenetics-based population pharmacokinetic analysis of gabapentin in patients with chronic pain: Effect of OCT2 and OCTN1 gene polymorphisms. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30192429/),l,86,12874,DB00996,Gabapentin
,30192429,clearance,"The absorption rate constant, volume of distribution, and clearance estimated were 0.44 h-1 , 86 L, and 17.3 × (estimated glomerular filtration ratio/89.58)1.04 L/h, respectively.",Pharmacogenetics-based population pharmacokinetic analysis of gabapentin in patients with chronic pain: Effect of OCT2 and OCTN1 gene polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30192429/),,17,12875,DB00996,Gabapentin
,21255527,total recovery,Mean total recovery of 14C-GEn-derived radioactivity was 99.3% (94.1% in urine and 5.2% in feces).,"A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21255527/),%,99.3,14053,DB00996,Gabapentin
,21255527,total recovery,Mean total recovery of 14C-GEn-derived radioactivity was 99.3% (94.1% in urine and 5.2% in feces).,"A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21255527/),%,94.1,14054,DB00996,Gabapentin
,21255527,total recovery,Mean total recovery of 14C-GEn-derived radioactivity was 99.3% (94.1% in urine and 5.2% in feces).,"A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21255527/),%,5.2,14055,DB00996,Gabapentin
,16337109,ED50,"In the high-intensity electroshock test, pregabalin potently inhibited tonic extensor seizures in rats (ED50 = 1.8 mg/kg, PO), and low-intensity electroshock seizures in mice.",Activity profile of pregabalin in rodent models of epilepsy and ataxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16337109/),[mg] / [kg],1.8,16032,DB00996,Gabapentin
,16337109,ED50,"It prevented tonic extensor seizures in the DBA/2 audiogenic mouse model (ED50 = 2.7 mg/kg, PO).",Activity profile of pregabalin in rodent models of epilepsy and ataxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16337109/),[mg] / [kg],2.7,16033,DB00996,Gabapentin
,16337109,ED50 1,"At higher dosages (ED50 1= 31 mg/kg, PO), pregabalin prevented clonic seizures from pentylenetetrazole in mice.",Activity profile of pregabalin in rodent models of epilepsy and ataxia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16337109/),[mg] / [kg],31,16034,DB00996,Gabapentin
,16404803,Milk/maternal plasma concentration ratios,"Milk/maternal plasma concentration ratios close to 1 demonstrate extensive transfer to breast milk of many AEDs including ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and zonisamide.",Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404803/),,1,16688,DB00996,Gabapentin
,17433926,serum concentration,"The average (+/-SD) carbamazepine (CBZ) dose is 8.8 +/- 4.7 mg/kg/day, yielding a mean serum concentration of 6.3 +/- 2.2 mg/liter.",Pharmacokinetics of antiepileptic drugs in elderly nursing home residents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433926/),[mg] / [l],6.3,18536,DB00996,Gabapentin
,9562133,AUC,"In a comparison of protein (phase IV) versus nonprotein phases (phases I-III), gabapentin AUC was 26% greater (47.28+/-14.65 vs. 37.43+/-9.78 microg/mL x h; p = 0.03), and Cmax was 32% higher (4.72+/-1.04 vs. 3.56+/-0.92 microg/mL; p = 0.003).",Gabapentin absorption: effect of mixing with foods of varying macronutrient composition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9562133/),[μg] / [h·ml],47.28,19030,DB00996,Gabapentin
,9562133,AUC,"In a comparison of protein (phase IV) versus nonprotein phases (phases I-III), gabapentin AUC was 26% greater (47.28+/-14.65 vs. 37.43+/-9.78 microg/mL x h; p = 0.03), and Cmax was 32% higher (4.72+/-1.04 vs. 3.56+/-0.92 microg/mL; p = 0.003).",Gabapentin absorption: effect of mixing with foods of varying macronutrient composition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9562133/),[μg] / [h·ml],37.43,19031,DB00996,Gabapentin
,9562133,Cmax,"In a comparison of protein (phase IV) versus nonprotein phases (phases I-III), gabapentin AUC was 26% greater (47.28+/-14.65 vs. 37.43+/-9.78 microg/mL x h; p = 0.03), and Cmax was 32% higher (4.72+/-1.04 vs. 3.56+/-0.92 microg/mL; p = 0.003).",Gabapentin absorption: effect of mixing with foods of varying macronutrient composition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9562133/),[μg] / [ml],4.72,19032,DB00996,Gabapentin
,9562133,Cmax,"In a comparison of protein (phase IV) versus nonprotein phases (phases I-III), gabapentin AUC was 26% greater (47.28+/-14.65 vs. 37.43+/-9.78 microg/mL x h; p = 0.03), and Cmax was 32% higher (4.72+/-1.04 vs. 3.56+/-0.92 microg/mL; p = 0.003).",Gabapentin absorption: effect of mixing with foods of varying macronutrient composition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9562133/),[μg] / [ml],3.56,19033,DB00996,Gabapentin
,22664749,Time to maximum plasma concentration,"Time to maximum plasma concentration was 7 to 9 hours, and elimination half-life was ~6 hours.","A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664749/),h,7 to 9,20373,DB00996,Gabapentin
,22664749,elimination half-life,"Time to maximum plasma concentration was 7 to 9 hours, and elimination half-life was ~6 hours.","A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664749/),h,6,20374,DB00996,Gabapentin
,29792353,half-life,"Gabapentin (GBP), an antiepileptic and anti-neuropathic agent, suffers from short half-life (5-7 h), has narrow absorption window, and is absorbed via carrier-mediated mechanism resulting in frequent dosing, poor compliance, and poor bioavailability (<60%).",Gastroretentive raft liquid delivery system as a new approach to release extension for carrier-mediated drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29792353/),h,5-7,24654,DB00996,Gabapentin
<,29792353,bioavailability,"Gabapentin (GBP), an antiepileptic and anti-neuropathic agent, suffers from short half-life (5-7 h), has narrow absorption window, and is absorbed via carrier-mediated mechanism resulting in frequent dosing, poor compliance, and poor bioavailability (<60%).",Gastroretentive raft liquid delivery system as a new approach to release extension for carrier-mediated drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29792353/),%,60,24655,DB00996,Gabapentin
,17609685,renal clearance (CL(R)),"In clinical studies, we found that in subjects homozygous for the L503F variant, gabapentin renal clearance (CL(R)) approximates the glomerular filtration rate (mean+/-SE: 110+/-12 ml/min, n=9), whereas in subjects homozygous for the reference allele, gabapentin undergoes net secretion in the kidney (141+/-7.8 ml/min, n=11, P<0.05).","Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17609685/),[ml] / [min],110,29796,DB00996,Gabapentin
,17609685,net secretion,"In clinical studies, we found that in subjects homozygous for the L503F variant, gabapentin renal clearance (CL(R)) approximates the glomerular filtration rate (mean+/-SE: 110+/-12 ml/min, n=9), whereas in subjects homozygous for the reference allele, gabapentin undergoes net secretion in the kidney (141+/-7.8 ml/min, n=11, P<0.05).","Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17609685/),[ml] / [min],141,29797,DB00996,Gabapentin
,10866910,area under the curve,"Concerning the pharmacokinetic variables of morphine and its glucuronides, no significant difference between morphine + placebo and morphine + GBP was observed, whereas the area under the curve of GBP (43.9 +/- 5.3 vs 63.4 +/- 16.2 microg.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),μg,43.9,29884,DB00996,Gabapentin
,10866910,area under the curve,"Concerning the pharmacokinetic variables of morphine and its glucuronides, no significant difference between morphine + placebo and morphine + GBP was observed, whereas the area under the curve of GBP (43.9 +/- 5.3 vs 63.4 +/- 16.2 microg.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),μg,63.4,29885,DB00996,Gabapentin
,10866910,apparent oral clearance,"mL(-1), P < 0.05) significantly increased, and apparent oral clearance (230.8 +/- 29.4 mL/min vs 178 +/- 97.9 mL/min, P = 0.06) and apparent renal clearance (86.9 +/- 20.6 vs 73.0 +/- 24.2 mL/min, P = 0.067) of GBP decreased when morphine was administered concomitantly.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),[ml] / [min],230.8,29886,DB00996,Gabapentin
,10866910,apparent oral clearance,"mL(-1), P < 0.05) significantly increased, and apparent oral clearance (230.8 +/- 29.4 mL/min vs 178 +/- 97.9 mL/min, P = 0.06) and apparent renal clearance (86.9 +/- 20.6 vs 73.0 +/- 24.2 mL/min, P = 0.067) of GBP decreased when morphine was administered concomitantly.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),[ml] / [min],178,29887,DB00996,Gabapentin
,10866910,apparent renal clearance,"mL(-1), P < 0.05) significantly increased, and apparent oral clearance (230.8 +/- 29.4 mL/min vs 178 +/- 97.9 mL/min, P = 0.06) and apparent renal clearance (86.9 +/- 20.6 vs 73.0 +/- 24.2 mL/min, P = 0.067) of GBP decreased when morphine was administered concomitantly.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),[ml] / [min],86.9,29888,DB00996,Gabapentin
,10866910,apparent renal clearance,"mL(-1), P < 0.05) significantly increased, and apparent oral clearance (230.8 +/- 29.4 mL/min vs 178 +/- 97.9 mL/min, P = 0.06) and apparent renal clearance (86.9 +/- 20.6 vs 73.0 +/- 24.2 mL/min, P = 0.067) of GBP decreased when morphine was administered concomitantly.",Gabapentin enhances the analgesic effect of morphine in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866910/),[ml] / [min],73.0,29889,DB00996,Gabapentin
,25383231,AUC,"In terms of AUC, there was an increase from 2471 ± 586 to 4560 ± 1396 ng·h/mL.",Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25383231/),[h·ng] / [ml],2471,31227,DB00996,Gabapentin
,25383231,AUC,"In terms of AUC, there was an increase from 2471 ± 586 to 4560 ± 1396 ng·h/mL.",Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25383231/),[h·ng] / [ml],4560,31228,DB00996,Gabapentin
,19854080,C(MAX),"The mean C(MAX) for the 10 and 20mg/kg groups were 8.54 and 13.22 microg/mL at 1.3 and 1.5h, and the terminal half-lives were 3.3 and 3.4h, respectively.",Pharmacokinetics of oral gabapentin in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19854080/),[μg] / [ml],8.54,37146,DB00996,Gabapentin
,19854080,C(MAX),"The mean C(MAX) for the 10 and 20mg/kg groups were 8.54 and 13.22 microg/mL at 1.3 and 1.5h, and the terminal half-lives were 3.3 and 3.4h, respectively.",Pharmacokinetics of oral gabapentin in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19854080/),[μg] / [ml],13.22,37147,DB00996,Gabapentin
,19854080,terminal half-lives,"The mean C(MAX) for the 10 and 20mg/kg groups were 8.54 and 13.22 microg/mL at 1.3 and 1.5h, and the terminal half-lives were 3.3 and 3.4h, respectively.",Pharmacokinetics of oral gabapentin in greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19854080/),h,3.3,37148,DB00996,Gabapentin
,19854080,terminal half-lives,"The mean C(MAX) for the 10 and 20mg/kg groups were 8.54 and 13.22 microg/mL at 1.3 and 1.5h, and the terminal half-lives were 3.3 and 3.4h, respectively.",Pharmacokinetics of oral gabapentin in greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19854080/),h,3.4,37149,DB00996,Gabapentin
,19854080,relative bioavailability,The relative bioavailability of the 10mg/kg group was 1.13 compared to the 20mg/kg group.,Pharmacokinetics of oral gabapentin in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19854080/),,1.13,37150,DB00996,Gabapentin
,22612015,T,"The mean values of pharmacokinetic parameters (mean +/- SD) were 3.17 +/- 0.80 hour (1.5 to 5.0 hour) for T; 4,853.58 +/- 1,369.67 ng/ml for Cm; 0.11 +/- 0.02 hour for Kel, 6.62 +/- 1.87 hour (4.89 to 11.41 hour) for T1/2; 47,712.88 +/- 12,853.61 ng.hour/ml for AUC0-t, 48,713.20 +/- 12,909.78 ng.hour/ml for AUC0-inf, 5.24 +/- 1.32 L/hour for CI, and 49.28 +/- 15.98 L for Vd.",Pharmacokinetic of gabapentin 600 mg tablet in Thai healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612015/),h,3.17,37382,DB00996,Gabapentin
,22612015,Cm,"The mean values of pharmacokinetic parameters (mean +/- SD) were 3.17 +/- 0.80 hour (1.5 to 5.0 hour) for T; 4,853.58 +/- 1,369.67 ng/ml for Cm; 0.11 +/- 0.02 hour for Kel, 6.62 +/- 1.87 hour (4.89 to 11.41 hour) for T1/2; 47,712.88 +/- 12,853.61 ng.hour/ml for AUC0-t, 48,713.20 +/- 12,909.78 ng.hour/ml for AUC0-inf, 5.24 +/- 1.32 L/hour for CI, and 49.28 +/- 15.98 L for Vd.",Pharmacokinetic of gabapentin 600 mg tablet in Thai healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612015/),[ng] / [ml],"4,853.58",37383,DB00996,Gabapentin
,22612015,Kel,"The mean values of pharmacokinetic parameters (mean +/- SD) were 3.17 +/- 0.80 hour (1.5 to 5.0 hour) for T; 4,853.58 +/- 1,369.67 ng/ml for Cm; 0.11 +/- 0.02 hour for Kel, 6.62 +/- 1.87 hour (4.89 to 11.41 hour) for T1/2; 47,712.88 +/- 12,853.61 ng.hour/ml for AUC0-t, 48,713.20 +/- 12,909.78 ng.hour/ml for AUC0-inf, 5.24 +/- 1.32 L/hour for CI, and 49.28 +/- 15.98 L for Vd.",Pharmacokinetic of gabapentin 600 mg tablet in Thai healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612015/),h,0.11,37384,DB00996,Gabapentin
,22612015,T1/2,"The mean values of pharmacokinetic parameters (mean +/- SD) were 3.17 +/- 0.80 hour (1.5 to 5.0 hour) for T; 4,853.58 +/- 1,369.67 ng/ml for Cm; 0.11 +/- 0.02 hour for Kel, 6.62 +/- 1.87 hour (4.89 to 11.41 hour) for T1/2; 47,712.88 +/- 12,853.61 ng.hour/ml for AUC0-t, 48,713.20 +/- 12,909.78 ng.hour/ml for AUC0-inf, 5.24 +/- 1.32 L/hour for CI, and 49.28 +/- 15.98 L for Vd.",Pharmacokinetic of gabapentin 600 mg tablet in Thai healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612015/),h,6.62,37385,DB00996,Gabapentin
,22612015,AUC0-t,"The mean values of pharmacokinetic parameters (mean +/- SD) were 3.17 +/- 0.80 hour (1.5 to 5.0 hour) for T; 4,853.58 +/- 1,369.67 ng/ml for Cm; 0.11 +/- 0.02 hour for Kel, 6.62 +/- 1.87 hour (4.89 to 11.41 hour) for T1/2; 47,712.88 +/- 12,853.61 ng.hour/ml for AUC0-t, 48,713.20 +/- 12,909.78 ng.hour/ml for AUC0-inf, 5.24 +/- 1.32 L/hour for CI, and 49.28 +/- 15.98 L for Vd.",Pharmacokinetic of gabapentin 600 mg tablet in Thai healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612015/),[h·ng] / [ml],"47,712.88",37386,DB00996,Gabapentin
,22612015,AUC0-inf,"The mean values of pharmacokinetic parameters (mean +/- SD) were 3.17 +/- 0.80 hour (1.5 to 5.0 hour) for T; 4,853.58 +/- 1,369.67 ng/ml for Cm; 0.11 +/- 0.02 hour for Kel, 6.62 +/- 1.87 hour (4.89 to 11.41 hour) for T1/2; 47,712.88 +/- 12,853.61 ng.hour/ml for AUC0-t, 48,713.20 +/- 12,909.78 ng.hour/ml for AUC0-inf, 5.24 +/- 1.32 L/hour for CI, and 49.28 +/- 15.98 L for Vd.",Pharmacokinetic of gabapentin 600 mg tablet in Thai healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612015/),[h·ng] / [ml],"48,713.20",37387,DB00996,Gabapentin
,22612015,CI,"The mean values of pharmacokinetic parameters (mean +/- SD) were 3.17 +/- 0.80 hour (1.5 to 5.0 hour) for T; 4,853.58 +/- 1,369.67 ng/ml for Cm; 0.11 +/- 0.02 hour for Kel, 6.62 +/- 1.87 hour (4.89 to 11.41 hour) for T1/2; 47,712.88 +/- 12,853.61 ng.hour/ml for AUC0-t, 48,713.20 +/- 12,909.78 ng.hour/ml for AUC0-inf, 5.24 +/- 1.32 L/hour for CI, and 49.28 +/- 15.98 L for Vd.",Pharmacokinetic of gabapentin 600 mg tablet in Thai healthy subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612015/),[l] / [h],5.24,37388,DB00996,Gabapentin
,22612015,Vd,"The mean values of pharmacokinetic parameters (mean +/- SD) were 3.17 +/- 0.80 hour (1.5 to 5.0 hour) for T; 4,853.58 +/- 1,369.67 ng/ml for Cm; 0.11 +/- 0.02 hour for Kel, 6.62 +/- 1.87 hour (4.89 to 11.41 hour) for T1/2; 47,712.88 +/- 12,853.61 ng.hour/ml for AUC0-t, 48,713.20 +/- 12,909.78 ng.hour/ml for AUC0-inf, 5.24 +/- 1.32 L/hour for CI, and 49.28 +/- 15.98 L for Vd.",Pharmacokinetic of gabapentin 600 mg tablet in Thai healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612015/),l,49.28,37389,DB00996,Gabapentin
,32360544,orally bioavailable,It was also found that SNAC is orally bioavailable (almost 40%) when dosed to rats.,Evaluating the Pharmacokinetics and Systemic Effects of a Permeability Enhancer Sodium N-[8-(2-hydroxybenzoyl)amino] Caprylate in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32360544/),%,40,40144,DB00996,Gabapentin
,15013156,Limit of detection,Limit of detection was 1.6ng/ml and lower limit of quantification was 7.5ng/ml.,Sample preparation and determination of gabapentin in venous and capillary blood using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013156/),[ng] / [ml],1.6,40291,DB00996,Gabapentin
,29149702,m/z transition,"These two compounds and gabapentin (internal standard) were extracted using a protein precipitation method with methanol and detected by Multiple Reaction Monitoring of m/z transition of 275.6-170.9, 217.7-113.1, and 172.5-154.3 for ET-26-HCl, ET-26-acid, and gabapentin respectively.",An HPLC tandem mass spectrometry for quantification of ET-26-HCl and its major metabolite in plasma and application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29149702/),,275.6-170.9,42389,DB00996,Gabapentin
,29149702,m/z transition,"These two compounds and gabapentin (internal standard) were extracted using a protein precipitation method with methanol and detected by Multiple Reaction Monitoring of m/z transition of 275.6-170.9, 217.7-113.1, and 172.5-154.3 for ET-26-HCl, ET-26-acid, and gabapentin respectively.",An HPLC tandem mass spectrometry for quantification of ET-26-HCl and its major metabolite in plasma and application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29149702/),,217.7-113.1,42390,DB00996,Gabapentin
,29149702,m/z transition,"These two compounds and gabapentin (internal standard) were extracted using a protein precipitation method with methanol and detected by Multiple Reaction Monitoring of m/z transition of 275.6-170.9, 217.7-113.1, and 172.5-154.3 for ET-26-HCl, ET-26-acid, and gabapentin respectively.",An HPLC tandem mass spectrometry for quantification of ET-26-HCl and its major metabolite in plasma and application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29149702/),,172.5-154.3,42391,DB00996,Gabapentin
,29149702,terminal phase elimination half-lives,The average terminal phase elimination half-lives were 0.87 and 1.03h for ET-26-HCl and ET-26-acid respectively.,An HPLC tandem mass spectrometry for quantification of ET-26-HCl and its major metabolite in plasma and application to a pharmacokinetic study in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29149702/),h,0.87,42392,DB00996,Gabapentin
,29149702,terminal phase elimination half-lives,The average terminal phase elimination half-lives were 0.87 and 1.03h for ET-26-HCl and ET-26-acid respectively.,An HPLC tandem mass spectrometry for quantification of ET-26-HCl and its major metabolite in plasma and application to a pharmacokinetic study in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29149702/),h,1.03,42393,DB00996,Gabapentin
,21713088,bioavailability,"Significant differences in PK parameters were observed between the manual group and the ADI/ABS group and respective bioavailability were measured (46.82 ± 19.45% and 61.54 ± 21.23%, respectively) which is 1.31-fold difference (P = 0.0051, P<0.05).",A comparative study of the pharmacokinetics of traditional and automated dosing/blood sampling systems using gabapentin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21713088/),%,46.82,42394,DB00996,Gabapentin
,21713088,bioavailability,"Significant differences in PK parameters were observed between the manual group and the ADI/ABS group and respective bioavailability were measured (46.82 ± 19.45% and 61.54 ± 21.23%, respectively) which is 1.31-fold difference (P = 0.0051, P<0.05).",A comparative study of the pharmacokinetics of traditional and automated dosing/blood sampling systems using gabapentin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21713088/),%,61.54,42395,DB00996,Gabapentin
,16821643,linear dynamic,The assay exhibited a linear dynamic range of 100-6000 ng/mL for miglitol in human plasma.,Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),[ng] / [ml],100-6000,52454,DB00996,Gabapentin
,16821643,absolute recoveries,"The average absolute recoveries of miglitol and the IS from spiked plasma samples were 40.5 +/- 2.7 and 47.1 +/- 2.9 %, respectively.",Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),%,40.5,52455,DB00996,Gabapentin
,16821643,absolute recoveries,"The average absolute recoveries of miglitol and the IS from spiked plasma samples were 40.5 +/- 2.7 and 47.1 +/- 2.9 %, respectively.",Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),%,47.1,52456,DB00996,Gabapentin
,16821643,run time,A run time of 2.5 min for each sample made it possible to analyze a throughput of more than 400 human plasma samples per day.,Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),min,2.5,52457,DB00996,Gabapentin
,16821643,observed maximum plasma concentration (Cmax),"The observed maximum plasma concentration (Cmax) of miglitol (100 mg oral dose) is 1740 ng/mL, time to observed maximum plasma concentration (tmax) is 3.5 h and elimination half-life (t(1/2)) is 2.5 h.",Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),[ng] / [ml],1740,52458,DB00996,Gabapentin
,16821643,time to observed maximum plasma concentration (tmax),"The observed maximum plasma concentration (Cmax) of miglitol (100 mg oral dose) is 1740 ng/mL, time to observed maximum plasma concentration (tmax) is 3.5 h and elimination half-life (t(1/2)) is 2.5 h.",Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),h,3.5,52459,DB00996,Gabapentin
,16821643,elimination half-life (t(1/2)),"The observed maximum plasma concentration (Cmax) of miglitol (100 mg oral dose) is 1740 ng/mL, time to observed maximum plasma concentration (tmax) is 3.5 h and elimination half-life (t(1/2)) is 2.5 h.",Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821643/),h,2.5,52460,DB00996,Gabapentin
,33118231,lag time,"Population estimates (between-subject variability in percentage) for lag time, first-order absorption rate, apparent volume of distribution and total clearance were 0.316 h (10.6%), 1.12 h-1 (10.7%), 140 L (7.7%) and 14.7 L/h (6.97%), respectively.",Population pharmacokinetics of gabapentin in patients with neuropathic pain: Lack of effect of diabetes or glycaemic control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33118231/),h,0.316,52566,DB00996,Gabapentin
,33118231,total clearance,"Population estimates (between-subject variability in percentage) for lag time, first-order absorption rate, apparent volume of distribution and total clearance were 0.316 h (10.6%), 1.12 h-1 (10.7%), 140 L (7.7%) and 14.7 L/h (6.97%), respectively.",Population pharmacokinetics of gabapentin in patients with neuropathic pain: Lack of effect of diabetes or glycaemic control. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33118231/),[l] / [h],14.7,52567,DB00996,Gabapentin
,22171585,CL/F,"Eslicarbazepine CL/F was affected by bodyweight, dose of carbamazepine (D(CAR)) and co-administration of barbiturates or phenytoin (AED(PB)), as predicted by the equation CL/F = (2.36 + 0.00149 • D(CAR) + 1.41 • AED(PB)) • (weight/70)0.75, which means that CL/F is 2.36 L/h for a subject with a bodyweight of 70 kg and without concomitant carbamazepine and barbiturates/phenytoin.","Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22171585/),[l] / [h],2.36,53544,DB00996,Gabapentin
,22206794,maximum plasma gabapentin concentration,"Mean maximum plasma gabapentin concentration was 5.77 μg/mL in patients with moderate and severe renal impairment, and 5.59 μg/mL in patients with end-stage renal disease who were undergoing hemodialysis.","Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22206794/),[μg] / [ml],5.77,54013,DB00996,Gabapentin
,22206794,maximum plasma gabapentin concentration,"Mean maximum plasma gabapentin concentration was 5.77 μg/mL in patients with moderate and severe renal impairment, and 5.59 μg/mL in patients with end-stage renal disease who were undergoing hemodialysis.","Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22206794/),[μg] / [ml],5.59,54014,DB00996,Gabapentin
,11554426,influx (CLin),"BBB influx (CLin) and efflux (CLout) permeability for pregabalin were 4.8 and 37.2 microL/min/g brain, respectively, following an intravenous infusion to rats.",Brain microdialysis and PK/PD correlation of pregabalin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554426/),[μl] / [brain·g·min],4.8,54621,DB00996,Gabapentin
,11554426,efflux (CLout) permeability,"BBB influx (CLin) and efflux (CLout) permeability for pregabalin were 4.8 and 37.2 microL/min/g brain, respectively, following an intravenous infusion to rats.",Brain microdialysis and PK/PD correlation of pregabalin in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554426/),[μl] / [brain·g·min],37.2,54622,DB00996,Gabapentin
,11554426,ECe50,"The resulting Ce (concentration in effect compartment) versus effect profile exhibits a sigmoidal curve and the calculated ECe50 and Keo values were 95.3 ng/mL and 0.0092 min-1, respectively.",Brain microdialysis and PK/PD correlation of pregabalin in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554426/),[ng] / [ml],95.3,54623,DB00996,Gabapentin
,11554426,Keo,"The resulting Ce (concentration in effect compartment) versus effect profile exhibits a sigmoidal curve and the calculated ECe50 and Keo values were 95.3 ng/mL and 0.0092 min-1, respectively.",Brain microdialysis and PK/PD correlation of pregabalin in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554426/),1/[min],0.0092,54624,DB00996,Gabapentin
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,58.4,55481,DB00996,Gabapentin
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,57.4,55482,DB00996,Gabapentin
,18806030,Peak Paco2,"Peak Paco2 was significantly higher in the amitriptyline group (58.4+/-1.6 mm Hg; mean SD, P<0.005) and in the combination group (57.4+/-1.0 mm Hg, P<0.02) than in the control group (50.2+/-5.2 mm Hg).","The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806030/),hg·mm,50.2,55483,DB00996,Gabapentin
,14985937,TID(20),"TID(20) values for TGB and GBP alone were 4.3 mg/kg and 70 mg/kg, respectively.",Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14985937/),[mg] / [kg],4.3,59880,DB00996,Gabapentin
,14985937,TID(20),"TID(20) values for TGB and GBP alone were 4.3 mg/kg and 70 mg/kg, respectively.",Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14985937/),[mg] / [kg],70,59881,DB00996,Gabapentin
,14985937,ED(50)),"Likewise, TGB and GBP injected alone suppressed the clonic phase of PTZ-induced seizures, with (effective) doses protecting 50% of the animals tested against clonic convulsions (ED(50)) for TGB and GBP of 0.9 and 199.3 mg/kg, respectively.",Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14985937/),[mg] / [kg],0.9,59882,DB00996,Gabapentin
,14985937,ED(50)),"Likewise, TGB and GBP injected alone suppressed the clonic phase of PTZ-induced seizures, with (effective) doses protecting 50% of the animals tested against clonic convulsions (ED(50)) for TGB and GBP of 0.9 and 199.3 mg/kg, respectively.",Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14985937/),[mg] / [kg],199.3,59883,DB00996,Gabapentin
,16112830,linear dynamic,The assay exhibited a linear dynamic range of 40-10000 ng/mL for gabapentin in human plasma.,Rapid quantification of gabapentin in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112830/),[ng] / [ml],40-10000,61126,DB00996,Gabapentin
,16112830,limit of detection,"The limit of detection and lower limit of quantification in human plasma were 10 and 40 ng/mL, respectively.",Rapid quantification of gabapentin in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112830/),[ng] / [ml],10,61127,DB00996,Gabapentin
,16112830,run time,A run time of 2 min for each sample made it possible to analyze a throughput of more than 400 human plasma samples per day.,Rapid quantification of gabapentin in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112830/),min,2,61128,DB00996,Gabapentin
,12576167,concentration at 1h (C(1h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],2.1,63306,DB00996,Gabapentin
,12576167,concentration at 12h (C(12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],0.8,63307,DB00996,Gabapentin
,12576167,area under the curve from 0 to 12h (AUC(0-12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],17.1,63308,DB00996,Gabapentin
,12576167,half-life (t(1/2)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),h,8.1,63309,DB00996,Gabapentin
,12576167,apparent oral clearance (CL/F),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),1/[mlmin],0.97,63310,DB00996,Gabapentin
,15146029,oral bioavailability,"In monkeys, oral bioavailability of gabapentin from XP13512 capsules was 84.2% compared with 25.4% after a similar oral Neurontin dose.","XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15146029/),%,84.2,67717,DB00996,Gabapentin
,15146029,oral bioavailability,"In monkeys, oral bioavailability of gabapentin from XP13512 capsules was 84.2% compared with 25.4% after a similar oral Neurontin dose.","XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15146029/),%,25.4,67718,DB00996,Gabapentin
,9864078,AUC at 72 hours,"For patients receiving gabapentin, the mean Li AUC at 72 hours was 9.91+/-3.54 mmol x hr/mL and did not differ significantly from the mean Li AUC of 10.19+/-2.89 mmol x hr/mL for patients receiving placebo.",Gabapentin does not alter single-dose lithium pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864078/),[h·mM] / [ml],9.91,72859,DB00996,Gabapentin
,9864078,AUC,"For patients receiving gabapentin, the mean Li AUC at 72 hours was 9.91+/-3.54 mmol x hr/mL and did not differ significantly from the mean Li AUC of 10.19+/-2.89 mmol x hr/mL for patients receiving placebo.",Gabapentin does not alter single-dose lithium pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864078/),[h·mM] / [ml],10.19,72860,DB00996,Gabapentin
,9864078,Li Cmax,The mean Li Cmax was 0.69+/-0.13 mmol/L for gabapentin patients and did not differ from the mean Li Cmax of 0.72+/-0.15 mmol/L for placebo patients.,Gabapentin does not alter single-dose lithium pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864078/),[mM] / [l],0.69,72861,DB00996,Gabapentin
,9864078,Li Cmax,The mean Li Cmax was 0.69+/-0.13 mmol/L for gabapentin patients and did not differ from the mean Li Cmax of 0.72+/-0.15 mmol/L for placebo patients.,Gabapentin does not alter single-dose lithium pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864078/),[mM] / [l],0.72,72862,DB00996,Gabapentin
,3730018,distribution coefficient,The distribution coefficient (octanol/buffer pH 7.4) is 7.5 X 10(-2).,"Pharmacokinetics and metabolism of gabapentin in rat, dog and man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730018/),,7.5 X 10(-2),73746,DB00996,Gabapentin
,3730018,Elimination half-lives,"Elimination half-lives range between 2-3 h in rats, 3-4 h in dogs, and 5-6 h in man.","Pharmacokinetics and metabolism of gabapentin in rat, dog and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730018/),h,2-3,73747,DB00996,Gabapentin
,3730018,Elimination half-lives,"Elimination half-lives range between 2-3 h in rats, 3-4 h in dogs, and 5-6 h in man.","Pharmacokinetics and metabolism of gabapentin in rat, dog and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730018/),h,3-4,73748,DB00996,Gabapentin
,3730018,Elimination half-lives,"Elimination half-lives range between 2-3 h in rats, 3-4 h in dogs, and 5-6 h in man.","Pharmacokinetics and metabolism of gabapentin in rat, dog and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730018/),h,5-6,73749,DB00996,Gabapentin
up to,3730018,Renal elimination,Renal elimination was up to 99.8% in rats and approx.,"Pharmacokinetics and metabolism of gabapentin in rat, dog and man. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3730018/),%,99.8,73750,DB00996,Gabapentin
,25794556,extraction ratio,Intermittent haemodialysis was performed for 4 h and resulted in a theophylline extraction ratio of 0.57 with elimination half-life of 2.3 h.,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),,0.57,74512,DB00996,Gabapentin
,25794556,elimination half-life,Intermittent haemodialysis was performed for 4 h and resulted in a theophylline extraction ratio of 0.57 with elimination half-life of 2.3 h.,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,2.3,74513,DB00996,Gabapentin
,25794556,extraction ratio,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),,0.46,74514,DB00996,Gabapentin
,25794556,half-life,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,5.3,74515,DB00996,Gabapentin
,25794556,half-life,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),,0.61,74516,DB00996,Gabapentin
,25794556,half-life,Theophylline extraction ratio ranged from 0.46 (half-life 5.3 h during the first cycle) to 0.61 (half-life 10.6 h during the second cycle).,Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,10.6,74517,DB00996,Gabapentin
,25794556,elimination half-life,"After cessation of SLED, elimination half-life was 26 h.",Intermittent haemodialysis and sustained low-efficiency dialysis (SLED) for acute theophylline toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25794556/),h,26,74518,DB00996,Gabapentin
,29551575,renal clearance,"Insulin treated diabetic animals showed higher renal clearance compared to control (vehicle + GAB: 0.25 [0.18-0.30] L/h·kg; DM + GAB + insulin: 0.55 [0.45-1.43] L/h·kg), which was attributed to the diabetes-induced glomerular hyperfiltration.","The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29551575/),[l] / [h·kg],0.25,77927,DB00996,Gabapentin
,29551575,renal clearance,"Insulin treated diabetic animals showed higher renal clearance compared to control (vehicle + GAB: 0.25 [0.18-0.30] L/h·kg; DM + GAB + insulin: 0.55 [0.45-1.43] L/h·kg), which was attributed to the diabetes-induced glomerular hyperfiltration.","The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29551575/),[l] / [h·kg],0.55,77928,DB00996,Gabapentin
,1373372,plasma elimination half-life,Plasma concentrations and plasma elimination half-life (4-6 h) of GBP were in agreement with the results of previous studies.,Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1373372/),h,4-6,79591,DB00996,Gabapentin
,1373372,CSF/plasma concentration ratio,The CSF/plasma concentration ratio of GBP 6 h after drug was 0.1.,Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1373372/),,0.1,79592,DB00996,Gabapentin
,1373372,CSF/plasma ratio,The CSF/plasma ratio at that time was 0.3.,Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1373372/),,0.3,79593,DB00996,Gabapentin
,22247871,m /,"The parent-to-product ion combination of m / z 160.2→55.1 and 172.2→95.0 was used to quantify PB and GB, respectively.",Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22247871/),,160.2,83468,DB00996,Gabapentin
,22247871,m /,"The parent-to-product ion combination of m / z 160.2→55.1 and 172.2→95.0 was used to quantify PB and GB, respectively.",Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22247871/),,55.1,83469,DB00996,Gabapentin
,22247871,m /,"The parent-to-product ion combination of m / z 160.2→55.1 and 172.2→95.0 was used to quantify PB and GB, respectively.",Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22247871/),,172.2,83470,DB00996,Gabapentin
,22247871,m /,"The parent-to-product ion combination of m / z 160.2→55.1 and 172.2→95.0 was used to quantify PB and GB, respectively.",Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22247871/),,95.,83471,DB00996,Gabapentin
,7600909,Oral bioavailability,"Oral bioavailability was 40% in monkeys administered 25 mg/kg, 79% in mice and rats receiving 50 mg/kg, and 80% in dogs administered 50 mg/kg.","Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600909/),%,40,84385,DB00996,Gabapentin
,7600909,Oral bioavailability,"Oral bioavailability was 40% in monkeys administered 25 mg/kg, 79% in mice and rats receiving 50 mg/kg, and 80% in dogs administered 50 mg/kg.","Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600909/),%,79,84386,DB00996,Gabapentin
,7600909,Oral bioavailability,"Oral bioavailability was 40% in monkeys administered 25 mg/kg, 79% in mice and rats receiving 50 mg/kg, and 80% in dogs administered 50 mg/kg.","Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600909/),%,80,84387,DB00996,Gabapentin
<,7600909,Binding,Binding to plasma proteins was < 3%.,"Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600909/),%,3,84388,DB00996,Gabapentin
,7600909,elimination half-life,"Mean intravenous elimination half-life was 1.7 hr in rats, 2.9 hr (14C only) in dogs, and 3.0 hr in monkeys.","Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600909/),h,1.7,84389,DB00996,Gabapentin
,7600909,elimination half-life,"Mean intravenous elimination half-life was 1.7 hr in rats, 2.9 hr (14C only) in dogs, and 3.0 hr in monkeys.","Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600909/),h,2.9,84390,DB00996,Gabapentin
,7600909,elimination half-life,"Mean intravenous elimination half-life was 1.7 hr in rats, 2.9 hr (14C only) in dogs, and 3.0 hr in monkeys.","Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600909/),h,3.0,84391,DB00996,Gabapentin
,15997234,ED50,"However, VPD (20-100 mg kg(- 1)), VCD (20-100 mg kg(- 1)) and DID (20-90 mg kg(- 1)) produced dose-related reversal of tactile allodynia with ED50 values of 61, 52 and 58 mgkg(- 1), respectively.",Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15997234/),1)·mgkg(-,61,84816,DB00996,Gabapentin
,15997234,ED50,"However, VPD (20-100 mg kg(- 1)), VCD (20-100 mg kg(- 1)) and DID (20-90 mg kg(- 1)) produced dose-related reversal of tactile allodynia with ED50 values of 61, 52 and 58 mgkg(- 1), respectively.",Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15997234/),1)·mgkg(-,52,84817,DB00996,Gabapentin
,15997234,ED50,"However, VPD (20-100 mg kg(- 1)), VCD (20-100 mg kg(- 1)) and DID (20-90 mg kg(- 1)) produced dose-related reversal of tactile allodynia with ED50 values of 61, 52 and 58 mgkg(- 1), respectively.",Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15997234/),1)·mgkg(-,58,84818,DB00996,Gabapentin
,15997234,ED50,All the amides were more potent than VPA (ED50=269 mgkg(- 1)).,Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15997234/),1)·mgkg(-,269,84819,DB00996,Gabapentin
,10667963,number of seizures,"Mean number of seizures/months was: 4.2 at baseline, 1.0 during the T.I.D., and 0.9 during the B.I.D. period.",Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10667963/),,4.2,87663,DB00996,Gabapentin
,10667963,number of seizures,"Mean number of seizures/months was: 4.2 at baseline, 1.0 during the T.I.D., and 0.9 during the B.I.D. period.",Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10667963/),,1.0,87664,DB00996,Gabapentin
,10667963,number of seizures,"Mean number of seizures/months was: 4.2 at baseline, 1.0 during the T.I.D., and 0.9 during the B.I.D. period.",Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10667963/),,0.9,87665,DB00996,Gabapentin
,10667963,trough plasma level,Mean trough plasma level of gabapentin was 5.9 microgram/ml during the T.I.D. and 5.2 microgram/ml during the B.I.D. period.,Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10667963/),[μg] / [ml],5.9,87666,DB00996,Gabapentin
,10667963,trough plasma level,Mean trough plasma level of gabapentin was 5.9 microgram/ml during the T.I.D. and 5.2 microgram/ml during the B.I.D. period.,Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10667963/),[μg] / [ml],5.2,87667,DB00996,Gabapentin
,17428017,m/z,"The ionization was optimized using ESI(+) and selectivity was achieved using MS/MS analysis, m/z 172.0 --> 154.0 and m/z 172.0 --> 126.0 for GB and IS, respectively.",Validated LC-MS/MS method for quantification of gabapentin in human plasma: application to pharmacokinetic and bioequivalence studies in Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428017/),,172.0,96070,DB00996,Gabapentin
,17428017,m/z,"The ionization was optimized using ESI(+) and selectivity was achieved using MS/MS analysis, m/z 172.0 --> 154.0 and m/z 172.0 --> 126.0 for GB and IS, respectively.",Validated LC-MS/MS method for quantification of gabapentin in human plasma: application to pharmacokinetic and bioequivalence studies in Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428017/),,154.0,96071,DB00996,Gabapentin
,17428017,m/z,"The ionization was optimized using ESI(+) and selectivity was achieved using MS/MS analysis, m/z 172.0 --> 154.0 and m/z 172.0 --> 126.0 for GB and IS, respectively.",Validated LC-MS/MS method for quantification of gabapentin in human plasma: application to pharmacokinetic and bioequivalence studies in Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428017/),,172.0,96072,DB00996,Gabapentin
,17517538,flow rate,The flow rate was set at 1.5 ml/min.,"Validated HPLC method for the determination of gabapentin in human plasma using pre-column derivatization with 1-fluoro-2,4-dinitrobenzene and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517538/),[ml] / [min],1.5,99007,DB00996,Gabapentin
,8681309,half-life,"At steady state, it has a half-life of 6-8 h, and is eliminated unchanged by renal route with a plasma clearance proportional to the creatinine clearance.","Gabapentin: pharmacokinetics, efficacy, and safety. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8681309/),h,6-8,105535,DB00996,Gabapentin
over,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,30,106800,DB00996,Gabapentin
,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,5-7,106801,DB00996,Gabapentin
,32213233,half maximal effective concentration,"The doses (30 and 80 mg/kg) and half maximal effective concentration (1.4 to 16.7 ng/mL) for this study were extrapolated from pharmacokinetic efficacy studies in rats, rabbits, and cats.",Pharmacokinetic Profiles of Gabapentin after Oral and Subcutaneous Administration in Black-tailed Prairie Dogs (Cynomys ludovicianus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32213233/),[ng] / [ml],1.4 to 16.7,108970,DB00996,Gabapentin
,32213233,peak plasma concentrations,"The peak plasma concentrations (mean ±1 SD) were 42.6 ±14.8 and 115.5 ±15.2 ng/mL, respectively, after 30 and 80 mg/kg SC and 14.5 ±3.5 and 20.7 ±6.1 ng/mL after the low and high oral dosages, respectively.",Pharmacokinetic Profiles of Gabapentin after Oral and Subcutaneous Administration in Black-tailed Prairie Dogs (Cynomys ludovicianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32213233/),[ng] / [ml],42.6,108971,DB00996,Gabapentin
,32213233,peak plasma concentrations,"The peak plasma concentrations (mean ±1 SD) were 42.6 ±14.8 and 115.5 ±15.2 ng/mL, respectively, after 30 and 80 mg/kg SC and 14.5 ±3.5 and 20.7 ±6.1 ng/mL after the low and high oral dosages, respectively.",Pharmacokinetic Profiles of Gabapentin after Oral and Subcutaneous Administration in Black-tailed Prairie Dogs (Cynomys ludovicianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32213233/),[ng] / [ml],115.5,108972,DB00996,Gabapentin
,32213233,peak plasma concentrations,"The peak plasma concentrations (mean ±1 SD) were 42.6 ±14.8 and 115.5 ±15.2 ng/mL, respectively, after 30 and 80 mg/kg SC and 14.5 ±3.5 and 20.7 ±6.1 ng/mL after the low and high oral dosages, respectively.",Pharmacokinetic Profiles of Gabapentin after Oral and Subcutaneous Administration in Black-tailed Prairie Dogs (Cynomys ludovicianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32213233/),[ng] / [ml],14.5,108973,DB00996,Gabapentin
,32213233,peak plasma concentrations,"The peak plasma concentrations (mean ±1 SD) were 42.6 ±14.8 and 115.5 ±15.2 ng/mL, respectively, after 30 and 80 mg/kg SC and 14.5 ±3.5 and 20.7 ±6.1 ng/mL after the low and high oral dosages, respectively.",Pharmacokinetic Profiles of Gabapentin after Oral and Subcutaneous Administration in Black-tailed Prairie Dogs (Cynomys ludovicianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32213233/),[ng] / [ml],20.7,108974,DB00996,Gabapentin
,32213233,Disappearance half-lives,"Disappearance half-lives for the low and high oral doses were 7.4 ± 6.0 h and 5.0 ± 0.8 h, respectively.",Pharmacokinetic Profiles of Gabapentin after Oral and Subcutaneous Administration in Black-tailed Prairie Dogs (Cynomys ludovicianus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32213233/),h,7.4,108975,DB00996,Gabapentin
,32213233,Disappearance half-lives,"Disappearance half-lives for the low and high oral doses were 7.4 ± 6.0 h and 5.0 ± 0.8 h, respectively.",Pharmacokinetic Profiles of Gabapentin after Oral and Subcutaneous Administration in Black-tailed Prairie Dogs (Cynomys ludovicianus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32213233/),h,5.0,108976,DB00996,Gabapentin
,23434065,terminal half-live,"In plasma, the terminal half-live of flunixin, meloxicam and gabapentin were 6.0 h (range, 3.4-11.0 h), 16.7h (range, 13.7-21.3h) and 15.3h (range, 11-32.9h), respectively.","A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23434065/),h,6.0,114728,DB00996,Gabapentin
,23434065,terminal half-live,"In plasma, the terminal half-live of flunixin, meloxicam and gabapentin were 6.0 h (range, 3.4-11.0 h), 16.7h (range, 13.7-21.3h) and 15.3h (range, 11-32.9h), respectively.","A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23434065/),h,16.7,114729,DB00996,Gabapentin
,23434065,terminal half-live,"In plasma, the terminal half-live of flunixin, meloxicam and gabapentin were 6.0 h (range, 3.4-11.0 h), 16.7h (range, 13.7-21.3h) and 15.3h (range, 11-32.9h), respectively.","A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23434065/),h,15.3,114730,DB00996,Gabapentin
,25567214,peak plasma concentration (C max),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[μg] / [ml],4.61,115254,DB00996,Gabapentin
,25567214,peak plasma concentration (C max),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[μg] / [ml],4.72,115255,DB00996,Gabapentin
,25567214,time to Cmax (t max),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),h,4.63,115256,DB00996,Gabapentin
,25567214,time to Cmax (t max),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),h,3.64,115257,DB00996,Gabapentin
,25567214,area under plasma concentration-time curve extrapolated to infinity (AUC0-∞),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[h·μg] / [ml],53.4,115258,DB00996,Gabapentin
,25567214,area under plasma concentration-time curve extrapolated to infinity (AUC0-∞),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[h·μg] / [ml],51.0,115259,DB00996,Gabapentin
,25567214,C max,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[ng] / [ml],154,115260,DB00996,Gabapentin
,25567214,C max,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[ng] / [ml],138,115261,DB00996,Gabapentin
,25567214,t max,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),h,1.45,115262,DB00996,Gabapentin
,25567214,t max,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),h,1.84,115263,DB00996,Gabapentin
,25567214,AUC0-∞,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[h·ng] / [ml],912,115264,DB00996,Gabapentin
,25567214,AUC0-∞,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[h·ng] / [ml],854,115265,DB00996,Gabapentin
,24486883,MTMD,The MTMD of LY545694 was 25mg twice daily.,"Safety, tolerability, pharmacokinetics, and effects on human experimental pain of the selective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24486883/),,25,116319,DB00996,Gabapentin
,16520099,flow rate,"The HPLC separation was achieved on a Phenomenex C(18) column (250 mm x 4.6 mm) using a mobile phase of acetonitrile-10mM orthophosphoric acid (pH 2.5) (77:23, v/v) solvent system at 1 mL/min flow rate.",Determination of tianeptine in human plasma using high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16520099/),[ml] / [min],1,116649,DB00996,Gabapentin
,16520099,detection limit (LOD),The detection limit (LOD) was found to be 2 ng/mL.,Determination of tianeptine in human plasma using high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16520099/),[ng] / [ml],2,116650,DB00996,Gabapentin
,16520099,recovery,The mean recovery was determined to be 88.6%.,Determination of tianeptine in human plasma using high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16520099/),%,88.6,116651,DB00996,Gabapentin
,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,50-400,122850,DB00996,Gabapentin
>,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,"15,000",122851,DB00996,Gabapentin
≤,21036913,minimal effective dose,KLYP961 also attenuated capsaicin-induced thermal allodynia in rhesus primates in a dose-related manner with a minimal effective dose (≤ 10 mg/kg p.o.) and a greater potency than gabapentin.,"Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),mg,10,122852,DB00996,Gabapentin
,19926351,flow-rate,"Chromatographic separation was achieved on a C(18) ACE((R)) column (50.0mmx2.1mm, 5mum, Advance Chromatography Technologies, Aberdeen, UK), using an isocratic mobile phase, consisting of water, methanol and formic acid (55:45:0.5, v/v/v), at a flow-rate of 0.3mL/min.",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),[ml] / [min],0.3,123111,DB00996,Gabapentin
,19926351,m/,"The transition monitored (positive mode) was m/z 279.1-->m/z 208.1 for triprolidine, m/z 165.9-->m/z 148.0 for pseudoephedrine and m/z 172.0-->m/z 154.0 for gabapentin (IS).",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),,279.1,123112,DB00996,Gabapentin
,19926351,m/z,"The transition monitored (positive mode) was m/z 279.1-->m/z 208.1 for triprolidine, m/z 165.9-->m/z 148.0 for pseudoephedrine and m/z 172.0-->m/z 154.0 for gabapentin (IS).",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),,165.9,123113,DB00996,Gabapentin
,19926351,m/z,"The transition monitored (positive mode) was m/z 279.1-->m/z 208.1 for triprolidine, m/z 165.9-->m/z 148.0 for pseudoephedrine and m/z 172.0-->m/z 154.0 for gabapentin (IS).",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),,172.0,123114,DB00996,Gabapentin
,19926351,m/,"The transition monitored (positive mode) was m/z 279.1-->m/z 208.1 for triprolidine, m/z 165.9-->m/z 148.0 for pseudoephedrine and m/z 172.0-->m/z 154.0 for gabapentin (IS).",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),,172.0,123115,DB00996,Gabapentin
,19926351,m/,"The transition monitored (positive mode) was m/z 279.1-->m/z 208.1 for triprolidine, m/z 165.9-->m/z 148.0 for pseudoephedrine and m/z 172.0-->m/z 154.0 for gabapentin (IS).",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),,154.0,123116,DB00996,Gabapentin
,19926351,ch,This method had a chromatographic run time of 5.0min and a linear calibration curves ranged from 0.2 to 20.0ng/mL for triprolidine and 5.0-500.0ng/mL for pseudoephedrine.,Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),min,5.0,123117,DB00996,Gabapentin
,19926351,run time,This method had a chromatographic run time of 5.0min and a linear calibration curves ranged from 0.2 to 20.0ng/mL for triprolidine and 5.0-500.0ng/mL for pseudoephedrine.,Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),min,5.0,123118,DB00996,Gabapentin
,19926351,recoveries,"The mean recoveries of triprolidine, pseudoephedrine and gabapentin were 93.6, 76.3 and 82.0% respectively.",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),%,93.6,123119,DB00996,Gabapentin
,19926351,recoveries,"The mean recoveries of triprolidine, pseudoephedrine and gabapentin were 93.6, 76.3 and 82.0% respectively.",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),%,76.3,123120,DB00996,Gabapentin
,19926351,recoveries,"The mean recoveries of triprolidine, pseudoephedrine and gabapentin were 93.6, 76.3 and 82.0% respectively.",Simultaneous determination of triprolidine and pseudoephedrine in human plasma by liquid chromatography-ion trap mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19926351/),%,82.0,123121,DB00996,Gabapentin
,20594085,apparent volume of the central compartment,"After IV administration, the mean +/- SEM apparent volume of the central compartment, apparent volume of distribution at steady state, and clearance and the harmonic mean +/- jackknife pseudo-SD for terminal half-life were 90.4 +/- 11.3 mL/kg, 650 +/- 14 mL/kg, 3 +/- 0.2 mL/min/kg, and 170 +/- 21 minutes, respectively.",Pharmacokinetics of gabapentin in cats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20594085/),[ml] / [kg],90.4,125809,DB00996,Gabapentin
,20594085,terminal half-life,"After IV administration, the mean +/- SEM apparent volume of the central compartment, apparent volume of distribution at steady state, and clearance and the harmonic mean +/- jackknife pseudo-SD for terminal half-life were 90.4 +/- 11.3 mL/kg, 650 +/- 14 mL/kg, 3 +/- 0.2 mL/min/kg, and 170 +/- 21 minutes, respectively.",Pharmacokinetics of gabapentin in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20594085/),min,170,125810,DB00996,Gabapentin
,20594085,systemic availability,"Mean +/- SD systemic availability and harmonic mean +/- jackknife pseudo-SD terminal half-life after oral administration were 88.7 +/- 11.1% and 177 +/- 25 minutes, respectively.",Pharmacokinetics of gabapentin in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20594085/),%,88.7,125811,DB00996,Gabapentin
,20594085,terminal half-life,"Mean +/- SD systemic availability and harmonic mean +/- jackknife pseudo-SD terminal half-life after oral administration were 88.7 +/- 11.1% and 177 +/- 25 minutes, respectively.",Pharmacokinetics of gabapentin in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20594085/),min,177,125812,DB00996,Gabapentin
,22372845,plasma C(max),The mean (±SD) plasma C(max) and T(max) for meloxicam (2.89±0.48 μg/mL and 11.33±4.12 h) were not much different from gabapentin at 10 mg/kg (2.87±0.2 μg/mL and 8±0 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),[μg] / [ml],2.89,126252,DB00996,Gabapentin
,22372845,plasma C(max),The mean (±SD) plasma C(max) and T(max) for meloxicam (2.89±0.48 μg/mL and 11.33±4.12 h) were not much different from gabapentin at 10 mg/kg (2.87±0.2 μg/mL and 8±0 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),[μg] / [ml],2.87,126253,DB00996,Gabapentin
,22372845,T(max),The mean (±SD) plasma C(max) and T(max) for meloxicam (2.89±0.48 μg/mL and 11.33±4.12 h) were not much different from gabapentin at 10 mg/kg (2.87±0.2 μg/mL and 8±0 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),h,11.33,126254,DB00996,Gabapentin
,22372845,T(max),The mean (±SD) plasma C(max) and T(max) for meloxicam (2.89±0.48 μg/mL and 11.33±4.12 h) were not much different from gabapentin at 10 mg/kg (2.87±0.2 μg/mL and 8±0 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),h,8,126255,DB00996,Gabapentin
,22372845,milk C(max),The mean (±SD) milk C(max) for meloxicam (0.41±80.16 μg/mL) was comparable to gabapentin at 10 mg/kg (0.63±0.13 μg/mL and 12±6.69 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),[μg] / [ml],0.41,126256,DB00996,Gabapentin
,22372845,milk C(max),The mean (±SD) milk C(max) for meloxicam (0.41±80.16 μg/mL) was comparable to gabapentin at 10 mg/kg (0.63±0.13 μg/mL and 12±6.69 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),[μg] / [ml],0.63,126257,DB00996,Gabapentin
,22372845,milk C(max),The mean (±SD) milk C(max) for meloxicam (0.41±80.16 μg/mL) was comparable to gabapentin at 10 mg/kg (0.63±0.13 μg/mL and 12±6.69 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),h,12,126258,DB00996,Gabapentin
,22372845,milk to plasma ratio,The mean (±SD) milk to plasma ratio for meloxicam (0.14±0.04) was lower than for gabapentin (0.23±0.06).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),,0.14,126259,DB00996,Gabapentin
,22372845,milk to plasma ratio,The mean (±SD) milk to plasma ratio for meloxicam (0.14±0.04) was lower than for gabapentin (0.23±0.06).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),,0.23,126260,DB00996,Gabapentin
,29018999,oral clearance,The oral clearance was estimated to be 11.1 L/h.,Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29018999/),[l] / [h],11.1,126333,DB00996,Gabapentin
,29018999,volume of distribution,The volume of distribution was characterized as 81.0 L.,Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29018999/),l,81.0,126334,DB00996,Gabapentin
,29018999,absorption rate constant,"The absorption rate constant was estimated at 0.860 h-1, and the lag time was predicted at 0.311 h.",Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29018999/),1/[h],0.860,126335,DB00996,Gabapentin
,29018999,lag time,"The absorption rate constant was estimated at 0.860 h-1, and the lag time was predicted at 0.311 h.",Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29018999/),h,0.311,126336,DB00996,Gabapentin
,29018999,Oral bioavailability,"Oral bioavailability was estimated to be 68.8% at dose of 300 mg, 62.7% at dose of 400 mg, and 47.1% at dose of 800 mg.",Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29018999/),%,68.8,126337,DB00996,Gabapentin
,29018999,Oral bioavailability,"Oral bioavailability was estimated to be 68.8% at dose of 300 mg, 62.7% at dose of 400 mg, and 47.1% at dose of 800 mg.",Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29018999/),%,62.7,126338,DB00996,Gabapentin
,29018999,Oral bioavailability,"Oral bioavailability was estimated to be 68.8% at dose of 300 mg, 62.7% at dose of 400 mg, and 47.1% at dose of 800 mg.",Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29018999/),%,47.1,126339,DB00996,Gabapentin
,30307652,CL,"After IV administration CL (median (range)) and terminal half-life were 160.67 mL/kg*hr (119.63-199.11) and 3.78 hours (3.12-4.47), respectively.",The pharmacokinetics of gabapentin in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307652/),[ml] / [h·kg],160.67,128167,DB00996,Gabapentin
,30307652,terminal half-life,"After IV administration CL (median (range)) and terminal half-life were 160.67 mL/kg*hr (119.63-199.11) and 3.78 hours (3.12-4.47), respectively.",The pharmacokinetics of gabapentin in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307652/),h,3.78,128168,DB00996,Gabapentin
,30307652,oral terminal half-life,"The oral terminal half-life was 3.63 hours (2.96-4.77), and 3.72 hours (3.12-4.51) for single and repeated dosing.",The pharmacokinetics of gabapentin in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307652/),h,3.63,128169,DB00996,Gabapentin
,30307652,oral terminal half-life,"The oral terminal half-life was 3.63 hours (2.96-4.77), and 3.72 hours (3.12-4.51) for single and repeated dosing.",The pharmacokinetics of gabapentin in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307652/),h,3.72,128170,DB00996,Gabapentin
,30307652,TMAX,"TMAX and CMAX , as predicted by the model were 1.05 hours (0.74-2.11), and 12.42 μg/mL (8.31-18.35) after single oral dosing, and 0.77 hours (0.58-1.64), and 14.78 μg/mL (9.70-18.41) after repeated oral dosing.",The pharmacokinetics of gabapentin in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307652/),h,1.05,128171,DB00996,Gabapentin
,30307652,CMAX,"TMAX and CMAX , as predicted by the model were 1.05 hours (0.74-2.11), and 12.42 μg/mL (8.31-18.35) after single oral dosing, and 0.77 hours (0.58-1.64), and 14.78 μg/mL (9.70-18.41) after repeated oral dosing.",The pharmacokinetics of gabapentin in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307652/),[μg] / [ml],12.42,128172,DB00996,Gabapentin
,30307652,CMAX,"TMAX and CMAX , as predicted by the model were 1.05 hours (0.74-2.11), and 12.42 μg/mL (8.31-18.35) after single oral dosing, and 0.77 hours (0.58-1.64), and 14.78 μg/mL (9.70-18.41) after repeated oral dosing.",The pharmacokinetics of gabapentin in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307652/),[μg] / [ml],14.78,128173,DB00996,Gabapentin
,30307652,Bioavailability,Bioavailability after a single oral dose was 94.77% (82.46-122.83).,The pharmacokinetics of gabapentin in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307652/),%,94.77,128174,DB00996,Gabapentin
,28243376,VAS,"The mean VAS values for pain at 24 hours for gabapentin vs. pregabalin were comparable (1.97±0.84 vs. 1.6±0.87, respectively; p=0.087) as were the results at one week after surgery (0.27±0.45 vs. 0.3±0.46, respectively; p=0.79).",Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28243376/),,1.97,130205,DB00996,Gabapentin
,28243376,VAS,"The mean VAS values for pain at 24 hours for gabapentin vs. pregabalin were comparable (1.97±0.84 vs. 1.6±0.87, respectively; p=0.087) as were the results at one week after surgery (0.27±0.45 vs. 0.3±0.46, respectively; p=0.79).",Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28243376/),,1.6,130206,DB00996,Gabapentin
,28243376,VAS,"The mean VAS values for pain at 24 hours for gabapentin vs. pregabalin were comparable (1.97±0.84 vs. 1.6±0.87, respectively; p=0.087) as were the results at one week after surgery (0.27±0.45 vs. 0.3±0.46, respectively; p=0.79).",Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28243376/),,0.27,130207,DB00996,Gabapentin
,28243376,VAS,"The mean VAS values for pain at 24 hours for gabapentin vs. pregabalin were comparable (1.97±0.84 vs. 1.6±0.87, respectively; p=0.087) as were the results at one week after surgery (0.27±0.45 vs. 0.3±0.46, respectively; p=0.79).",Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28243376/),,0.3,130208,DB00996,Gabapentin
,20869892,C(max),"The mean (± standard deviation, SD) C(max), T(max) and elimination half-life (t(½)λz) for gabapentin (10mg/kg) alone was 2.97 ± 0.40μg/mL, 9.33 ± 2.73h and 11.02 ± 3.68h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),[μg] / [ml],2.97,132618,DB00996,Gabapentin
,20869892,T(max),"The mean (± standard deviation, SD) C(max), T(max) and elimination half-life (t(½)λz) for gabapentin (10mg/kg) alone was 2.97 ± 0.40μg/mL, 9.33 ± 2.73h and 11.02 ± 3.68h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,9.33,132619,DB00996,Gabapentin
,20869892,elimination half-life (t(½)λz),"The mean (± standard deviation, SD) C(max), T(max) and elimination half-life (t(½)λz) for gabapentin (10mg/kg) alone was 2.97 ± 0.40μg/mL, 9.33 ± 2.73h and 11.02 ± 3.68h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,11.02,132620,DB00996,Gabapentin
,20869892,C(max),"The mean (± SD) C(max), T(max) and t(½)λz for gabapentin (15mg/kg) co-administered with meloxicam was 3.57±1.04μg/mL, 7.33 ± 1.63h and 8.12±2.11h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),[μg] / [ml],3.57,132621,DB00996,Gabapentin
,20869892,T(max),"The mean (± SD) C(max), T(max) and t(½)λz for gabapentin (15mg/kg) co-administered with meloxicam was 3.57±1.04μg/mL, 7.33 ± 1.63h and 8.12±2.11h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,7.33,132622,DB00996,Gabapentin
,20869892,t(½)λz,"The mean (± SD) C(max), T(max) and t(½)λz for gabapentin (15mg/kg) co-administered with meloxicam was 3.57±1.04μg/mL, 7.33 ± 1.63h and 8.12±2.11h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,8.12,132623,DB00996,Gabapentin
,20869892,C(max),"The mean (±SD) C(max), T(max) and t(½)λz for meloxicam was 2.11± 0.19μg/mL, 11.67 ± 3.44h and 20.47 ± 9.22h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),[μg] / [ml],2.11,132624,DB00996,Gabapentin
,20869892,T(max),"The mean (±SD) C(max), T(max) and t(½)λz for meloxicam was 2.11± 0.19μg/mL, 11.67 ± 3.44h and 20.47 ± 9.22h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,11.67,132625,DB00996,Gabapentin
,20869892,t(½)λz,"The mean (±SD) C(max), T(max) and t(½)λz for meloxicam was 2.11± 0.19μg/mL, 11.67 ± 3.44h and 20.47 ± 9.22h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,20.47,132626,DB00996,Gabapentin
,19886325,half-life,Its half-life of 5 - 9 hours is increased to up to 132 hours in anuric patients.,Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19886325/),h,5 - 9,132995,DB00996,Gabapentin
up to,19886325,half-life,Its half-life of 5 - 9 hours is increased to up to 132 hours in anuric patients.,Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19886325/),h,132,132996,DB00996,Gabapentin
,19886325,plasma half-life,Its normal plasma half-life is 2 - 3 hours; dosage modifications are obligatory in renal insufficiency.,Drug-induced encephalopathy secondary to non renal dosing of common medications in Two dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19886325/),h,2 - 3,132997,DB00996,Gabapentin
,26006328,biological half life,Gabapentin was selected to formulate oral controlled release dry suspension because of short biological half life of 5-7 h and low bioavailability (60%).,Nanosponge-based pediatric-controlled release dry suspension of Gabapentin for reconstitution. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006328/),h,5-7,134116,DB00996,Gabapentin
,26006328,bioavailability,Gabapentin was selected to formulate oral controlled release dry suspension because of short biological half life of 5-7 h and low bioavailability (60%).,Nanosponge-based pediatric-controlled release dry suspension of Gabapentin for reconstitution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006328/),%,60,134117,DB00996,Gabapentin
>,19808136,oral bioavailability,Gabapentin enacarbil is an actively transported prodrug of gabapentin that provides predictable dose-proportional gabapentin exposure with high (> or =68%) oral bioavailability.,"Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19808136/),%,68,135696,DB00996,Gabapentin
,8925804,Cmax,"Cmax was significantly increased by 36% (3.87 +/- 1.15 vs 5.28 +/- .97 micrograms/ml, P = 0.002), and Tmax tended to be shorter (3.9 +/- 1.8 vs 2.8 +/- .35 h, P = 0.10), after the high-protein meal.",Effect of a high-protein meal on gabapentin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925804/),[μg] / [ml],3.87,136534,DB00996,Gabapentin
,8925804,Cmax,"Cmax was significantly increased by 36% (3.87 +/- 1.15 vs 5.28 +/- .97 micrograms/ml, P = 0.002), and Tmax tended to be shorter (3.9 +/- 1.8 vs 2.8 +/- .35 h, P = 0.10), after the high-protein meal.",Effect of a high-protein meal on gabapentin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925804/),[μg] / [ml],5.28,136535,DB00996,Gabapentin
,8925804,Tmax,"Cmax was significantly increased by 36% (3.87 +/- 1.15 vs 5.28 +/- .97 micrograms/ml, P = 0.002), and Tmax tended to be shorter (3.9 +/- 1.8 vs 2.8 +/- .35 h, P = 0.10), after the high-protein meal.",Effect of a high-protein meal on gabapentin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925804/),h,3.9,136536,DB00996,Gabapentin
,8925804,Tmax,"Cmax was significantly increased by 36% (3.87 +/- 1.15 vs 5.28 +/- .97 micrograms/ml, P = 0.002), and Tmax tended to be shorter (3.9 +/- 1.8 vs 2.8 +/- .35 h, P = 0.10), after the high-protein meal.",Effect of a high-protein meal on gabapentin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925804/),h,2.8,136537,DB00996,Gabapentin
,22242459,flow-rate,"After a single plasma protein precipitation with methanol, gabapentin and metformin (internal standard) were chromatographed on a Inertsil ODS-3 column (50 mm x 2.1 mm ID, 3 microm) with mobile phase consisting of methanol-0.2% formic acid aqueous solution (80:20, v/v) at a flow-rate of 0.2 mL x min(-1).",[LC-MS/MS method for quantification and pharmacokinetic study of gabapentin in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242459/),[ml] / [min],0.2,136754,DB00996,Gabapentin
,22242459,run time,The run time was 2.2 min.,[LC-MS/MS method for quantification and pharmacokinetic study of gabapentin in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242459/),min,2.2,136755,DB00996,Gabapentin
,17380260,oral absorption,"In agreement, the oral absorption of gabapentin, relative to the intravenous dose, was 79% after glycyl-glutamate loading but only 47% when drug was administered alone.",In vivo effects of glycyl-glutamate and glycyl-sarcosine on gabapentin oral absorption in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17380260/),%,79,142062,DB00996,Gabapentin
,17380260,oral absorption,"In agreement, the oral absorption of gabapentin, relative to the intravenous dose, was 79% after glycyl-glutamate loading but only 47% when drug was administered alone.",In vivo effects of glycyl-glutamate and glycyl-sarcosine on gabapentin oral absorption in rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17380260/),%,47,142063,DB00996,Gabapentin
,33978255,volume of the central compartment,"Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively.",Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33978255/),[ml] / [kg],170,158342,DB00996,Gabapentin
,33978255,clearance,"Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively.",Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33978255/),[ml] / [kg],170,158343,DB00996,Gabapentin
,33978255,clearance,"Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively.",Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33978255/),[ml] / [kg·min],1.2,158344,DB00996,Gabapentin
,33978255,volume of distribution at steady-state,"Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively.",Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33978255/),[ml] / [kg],170,158345,DB00996,Gabapentin
,33978255,volume of distribution at steady-state,"Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively.",Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33978255/),[ml] / [kg·min],1.2,158346,DB00996,Gabapentin
,33978255,terminal half-life,"Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively.",Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33978255/),[ml] / [kg],594,158347,DB00996,Gabapentin
,33978255,terminal half-life,"Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively.",Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33978255/),min,360,158348,DB00996,Gabapentin
,33978255,absorption half-life,"For the oral route, absorption half-life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively.",Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa). ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33978255/),min,58,158349,DB00996,Gabapentin
,33978255,maximal plasma concentration,"For the oral route, absorption half-life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively.",Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33978255/),[ng] / [ml],9155,158350,DB00996,Gabapentin
,33978255,time to reach maximal plasma concentration,"For the oral route, absorption half-life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively.",Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33978255/),min,194,158351,DB00996,Gabapentin
,33978255,oral bioavailability,Estimated oral bioavailability was 47%.,Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33978255/),%,47,158352,DB00996,Gabapentin
,17144644,bioavailable,"Pregabalin is rapidly absorbed with at least 90% bioavailable irrespective of dose, does not bind to plasma proteins and is excreted virtually unchanged by the kidneys.",[Pregabalin (Lyrica) and neuropathic pain syndromes]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17144644/),%,90,159783,DB00996,Gabapentin
,9714500,F,"At 3600 mg/day, mean F following t.i.d. and q.i.d. dosing were 38.7+/-22.1% and 40.0+/-18.9%, respectively (P=0.738).",Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9714500/),%,38.7,159790,DB00996,Gabapentin
,9714500,F,"At 3600 mg/day, mean F following t.i.d. and q.i.d. dosing were 38.7+/-22.1% and 40.0+/-18.9%, respectively (P=0.738).",Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9714500/),%,40.0,159791,DB00996,Gabapentin
,9714500,F,"At 4800 mg/day, mean F following t.i.d. and q.i.d. dosing were 29.2+/-16.2% and 35.6+/-17.6%, respectively (P=0.006).",Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9714500/),%,29.2,159792,DB00996,Gabapentin
,9714500,F,"At 4800 mg/day, mean F following t.i.d. and q.i.d. dosing were 29.2+/-16.2% and 35.6+/-17.6%, respectively (P=0.006).",Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9714500/),%,35.6,159793,DB00996,Gabapentin
,23251735,C(max),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the test formulation (Pregobin™) of pregabalin were 2.10 (0.56) μg/ml, 10.35 (2.00) μgxh/ml and 13.92 (2.74) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[μg] / [ml],2.10,171096,DB00996,Gabapentin
,23251735,AUC(0-t),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the test formulation (Pregobin™) of pregabalin were 2.10 (0.56) μg/ml, 10.35 (2.00) μgxh/ml and 13.92 (2.74) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[μg] / [ml],2.10,171097,DB00996,Gabapentin
,23251735,AUC(0-t),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the test formulation (Pregobin™) of pregabalin were 2.10 (0.56) μg/ml, 10.35 (2.00) μgxh/ml and 13.92 (2.74) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[h·μg] / [ml],10.35,171098,DB00996,Gabapentin
,23251735,AUC(0-∞),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the test formulation (Pregobin™) of pregabalin were 2.10 (0.56) μg/ml, 10.35 (2.00) μgxh/ml and 13.92 (2.74) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[h·μg] / [ml],13.92,171099,DB00996,Gabapentin
,23251735,C(max),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the reference formulation (Lyrica™) of pregabalin were 2.15 (0.52) μg/ml, 10.31 (1.85) μgxh/ml and 13.78 (2.25) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[μg] / [ml],2.15,171100,DB00996,Gabapentin
,23251735,AUC(0-t),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the reference formulation (Lyrica™) of pregabalin were 2.15 (0.52) μg/ml, 10.31 (1.85) μgxh/ml and 13.78 (2.25) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[μg] / [ml],2.15,171101,DB00996,Gabapentin
,23251735,AUC(0-t),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the reference formulation (Lyrica™) of pregabalin were 2.15 (0.52) μg/ml, 10.31 (1.85) μgxh/ml and 13.78 (2.25) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[h·μg] / [ml],10.31,171102,DB00996,Gabapentin
,23251735,AUC(0-∞),"The mean (SD) C(max), AUC(0-t) and AUC(0-∞) of the reference formulation (Lyrica™) of pregabalin were 2.15 (0.52) μg/ml, 10.31 (1.85) μgxh/ml and 13.78 (2.25) μgxh/ml, respectively.",A comparative bioavailability study of two formulations of pregabalin in healthy Chilean volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23251735/),[h·μg] / [ml],13.78,171103,DB00996,Gabapentin
,15584938,C(max),The C(max) from 0.9 to 5.8 microg/mL (mean: 2.6 +/- 1.7 microg/mL) and T(max) from 0.5 to 2.0 h (mean: 1.6 +/- 1.0 h).,Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15584938/),[μg] / [ml],0.9 to 5.8,172206,DB00996,Gabapentin
,15584938,C(max),The C(max) from 0.9 to 5.8 microg/mL (mean: 2.6 +/- 1.7 microg/mL) and T(max) from 0.5 to 2.0 h (mean: 1.6 +/- 1.0 h).,Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15584938/),[μg] / [ml],2.6,172207,DB00996,Gabapentin
,15584938,T(max),The C(max) from 0.9 to 5.8 microg/mL (mean: 2.6 +/- 1.7 microg/mL) and T(max) from 0.5 to 2.0 h (mean: 1.6 +/- 1.0 h).,Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15584938/),h,1.6,172208,DB00996,Gabapentin
,15584938,apparent clearance (Cl/F),"The apparent clearance (Cl/F) ranged from 0.12 to 1.12 L/h/kg (mean: 0.50 +/- 0.29 L/h/kg), and the elimination half-life from 3.2 to 12.2 h (mean: 5.5 +/- 0.8 h).",Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15584938/),[l] / [h·kg],0.50,172209,DB00996,Gabapentin
,15584938,elimination half-life,"The apparent clearance (Cl/F) ranged from 0.12 to 1.12 L/h/kg (mean: 0.50 +/- 0.29 L/h/kg), and the elimination half-life from 3.2 to 12.2 h (mean: 5.5 +/- 0.8 h).",Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15584938/),h,5.5,172210,DB00996,Gabapentin
,8022536,elimination half-life,The elimination half-life is approximately 5 to 9 hours.,Clinical pharmacokinetics of gabapentin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8022536/),h,5 to 9,175886,DB00996,Gabapentin
,8692732,CL1,"The values for CL1 and CL2 were 0.042 (0.017) and 0.36 (0.16) ml/min.g-brain, respectively, indicating that GBP was more efficiently transported from brain ECF to plasma.",The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692732/),[ml] / [g-brain·min],0.042,177551,DB00996,Gabapentin
,8692732,CL2,"The values for CL1 and CL2 were 0.042 (0.017) and 0.36 (0.16) ml/min.g-brain, respectively, indicating that GBP was more efficiently transported from brain ECF to plasma.",The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8692732/),[ml] / [g-brain·min],0.36,177552,DB00996,Gabapentin
,23743781,ED50,"The ED50 was 3,080 mg/day for bioavailable dose or 3,370 mg/day for steady-state concentration; and the maximum exposure was 2,340 mg/day or 16.9 mg/L.",Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743781/),[mg] / [d],"3,080",179678,DB00996,Gabapentin
,23743781,bioavailable dose,"The ED50 was 3,080 mg/day for bioavailable dose or 3,370 mg/day for steady-state concentration; and the maximum exposure was 2,340 mg/day or 16.9 mg/L.",Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743781/),[mg] / [d],"3,080",179679,DB00996,Gabapentin
,23743781,steady-state concentration,"The ED50 was 3,080 mg/day for bioavailable dose or 3,370 mg/day for steady-state concentration; and the maximum exposure was 2,340 mg/day or 16.9 mg/L.",Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743781/),[mg] / [d],"3,370",179680,DB00996,Gabapentin
,23743781,maximum exposure,"The ED50 was 3,080 mg/day for bioavailable dose or 3,370 mg/day for steady-state concentration; and the maximum exposure was 2,340 mg/day or 16.9 mg/L.",Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743781/),[mg] / [d],"2,340",179681,DB00996,Gabapentin
,23743781,maximum exposure,"The ED50 was 3,080 mg/day for bioavailable dose or 3,370 mg/day for steady-state concentration; and the maximum exposure was 2,340 mg/day or 16.9 mg/L.",Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23743781/),[mg] / [l],16.9,179682,DB00996,Gabapentin
,16234874,oral bioavailability,Peak plasma levels occur approximately 1 hour after oral doses and oral bioavailability is about 90%.,Pregabalin: a new agent for the treatment of neuropathic pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16234874/),%,90,181695,DB00996,Gabapentin
,16234874,plasma half-life,"Pregabalin is not protein-bound and exhibits a plasma half-life of about 6 hours, which is not dose-dependent.",Pregabalin: a new agent for the treatment of neuropathic pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16234874/),h,6,181696,DB00996,Gabapentin
,7665723,maximum gabapentin plasma concentration,A mean (SD) maximum gabapentin plasma concentration of 6.0 (2.4) micrograms/mL was achieved at 4.7 (2.1) hours post-dose.,Disposition of gabapentin in anuric subjects on hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665723/),[μg] / [ml],6.0,183098,DB00996,Gabapentin
,7665723,elimination half-life,The elimination half-life of gabapentin on non-hemodialysis days averaged 132 hours.,Disposition of gabapentin in anuric subjects on hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665723/),h,132,183099,DB00996,Gabapentin
,7665723,clearance,"Approximately 35% of the gabapentin dose was recovered in dialysate, and mean hemodialysis clearance of gabapentin was 142 (26) mL/min; approximately 93% of the dialyzer creatinine clearance.",Disposition of gabapentin in anuric subjects on hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665723/),[ml] / [min],142,183100,DB00996,Gabapentin
,7665723,elimination half-life,Gabapentin elimination half-life during hemodialysis was approximately 4 hours.,Disposition of gabapentin in anuric subjects on hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665723/),h,4,183101,DB00996,Gabapentin
,21276028,run time,The derivatization of gabapentin was optimized and HPLC separation was achieved over an ODS column with a run time of 3·5 min.,Rapid and validated fluorometric HPLC method for determination of gabapentin in human plasma and urine for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21276028/),min,3·5,185557,DB00996,Gabapentin
,32238455,dissociate rate constants,"The dissociate rate constants of TPPU and TCPU were predicted to be 2.24 and 2.67 hours-1, respectively, which is close to the values obtained from in vitro experiments.",Simultaneous Target-Mediated Drug Disposition Model for Two Small-Molecule Compounds Competing for Their Pharmacological Target: Soluble Epoxide Hydrolase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238455/),1/[h],2.24,188072,DB00996,Gabapentin
,32238455,dissociate rate constants,"The dissociate rate constants of TPPU and TCPU were predicted to be 2.24 and 2.67 hours-1, respectively, which is close to the values obtained from in vitro experiments.",Simultaneous Target-Mediated Drug Disposition Model for Two Small-Molecule Compounds Competing for Their Pharmacological Target: Soluble Epoxide Hydrolase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238455/),1/[h],2.67,188073,DB00996,Gabapentin
,32149389,half [IC50 ],"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[μM] / [l],237,207864,DB00996,Gabapentin
,32149389,IC50,"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[nM] / [l],1.1,207865,DB00996,Gabapentin
,32149389,IC50,"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[nM] / [l],39,207866,DB00996,Gabapentin
,32149389,IC50,"GBP has low apparent affinity for OCT2 (concentration of an inhibitor where the response [or binding] is reduced by half [IC50 ] 237 µmol/L) and a high apparent affinity for hMATE1 (IC50 1.1 nmol/L), hMATE2-K (IC50 39 nmol/L), and hOCTN1 (IC50 2.1 nmol/L) in HEK cells.",Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32149389/),[nM] / [l],2.1,207867,DB00996,Gabapentin
,22325733,ddQTcIb,"The maximum ddQTcIb values were 0.7 msec (upper 95% confidence limit [CL], 3.0) with gabapentin enacarbil 1200 mg; 1.3 msec (upper CL, 3.6) with gabapentin enacarbil 6000 mg; and 7.4 msec (lower CL, 5.1) with moxifloxacin.","Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22325733/),ms,0.7,207903,DB00996,Gabapentin
,22325733,ddQTcIb,"The maximum ddQTcIb values were 0.7 msec (upper 95% confidence limit [CL], 3.0) with gabapentin enacarbil 1200 mg; 1.3 msec (upper CL, 3.6) with gabapentin enacarbil 6000 mg; and 7.4 msec (lower CL, 5.1) with moxifloxacin.","Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22325733/),ms,1.3,207904,DB00996,Gabapentin
,22325733,ddQTcIb,"The maximum ddQTcIb values were 0.7 msec (upper 95% confidence limit [CL], 3.0) with gabapentin enacarbil 1200 mg; 1.3 msec (upper CL, 3.6) with gabapentin enacarbil 6000 mg; and 7.4 msec (lower CL, 5.1) with moxifloxacin.","Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22325733/),ms,7.4,207905,DB00996,Gabapentin
,12548145,Apparent oral clearance,"Apparent oral clearance values (mean +/- SD) in children aged 6 years or less (4.8 +/- 0.9 mL/kg/min) were comparable with those observed in children aged 7 to 15 years (4.6 + 1.5 mL/kg/min) and moderately higher than those found in young adults (3.9 + 0.9 mL/kg/min), even though differences among groups failed to reach statistical significance.","Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548145/),[ml] / [kg·min],4.8,209151,DB00996,Gabapentin
,12548145,Apparent oral clearance,"Apparent oral clearance values (mean +/- SD) in children aged 6 years or less (4.8 +/- 0.9 mL/kg/min) were comparable with those observed in children aged 7 to 15 years (4.6 + 1.5 mL/kg/min) and moderately higher than those found in young adults (3.9 + 0.9 mL/kg/min), even though differences among groups failed to reach statistical significance.","Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548145/),[ml] / [kg·min],4.6,209152,DB00996,Gabapentin
,12548145,Apparent oral clearance,"Apparent oral clearance values (mean +/- SD) in children aged 6 years or less (4.8 +/- 0.9 mL/kg/min) were comparable with those observed in children aged 7 to 15 years (4.6 + 1.5 mL/kg/min) and moderately higher than those found in young adults (3.9 + 0.9 mL/kg/min), even though differences among groups failed to reach statistical significance.","Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548145/),[ml] / [kg·min],3.9,209153,DB00996,Gabapentin
,12548145,CL/F,"There was, however, a significant difference in CL/F between children aged 10 years or less and older children (5.1 +/- 1.1 vs. 3.8 +/- 1.2 mL/kg/min, P < 0.005).","Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548145/),[ml] / [kg·min],5.1,209154,DB00996,Gabapentin
,12548145,CL/F,"There was, however, a significant difference in CL/F between children aged 10 years or less and older children (5.1 +/- 1.1 vs. 3.8 +/- 1.2 mL/kg/min, P < 0.005).","Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548145/),[ml] / [kg·min],3.8,209155,DB00996,Gabapentin
,20818832,absolute bioavailability,"The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at > or = 90% irrespective of the dosage.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),%,60,209278,DB00996,Gabapentin
,20818832,absolute bioavailability,"The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at > or = 90% irrespective of the dosage.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),%,33,209279,DB00996,Gabapentin
> or =,20818832,absolute bioavailability,"The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at > or = 90% irrespective of the dosage.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),%,90,209280,DB00996,Gabapentin
,20818832,elimination half-lives,"Both drugs are excreted renally, with elimination half-lives of approximately 6 hours.",A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818832/),h,6,209281,DB00996,Gabapentin
,18827074,time to maximum concentration,"Compared with 600 mg gabapentin, an equimolar XP13512 extended-release dose provided extended gabapentin exposure (time to maximum concentration, 8.4 vs 2.7 hours) and superior bioavailability (74.5% vs 36.6%).","Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18827074/),h,8.4,212238,DB00996,Gabapentin
,18827074,time to maximum concentration,"Compared with 600 mg gabapentin, an equimolar XP13512 extended-release dose provided extended gabapentin exposure (time to maximum concentration, 8.4 vs 2.7 hours) and superior bioavailability (74.5% vs 36.6%).","Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18827074/),h,2.7,212239,DB00996,Gabapentin
,18827074,bioavailability,"Compared with 600 mg gabapentin, an equimolar XP13512 extended-release dose provided extended gabapentin exposure (time to maximum concentration, 8.4 vs 2.7 hours) and superior bioavailability (74.5% vs 36.6%).","Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18827074/),%,74.5,212240,DB00996,Gabapentin
,18827074,bioavailability,"Compared with 600 mg gabapentin, an equimolar XP13512 extended-release dose provided extended gabapentin exposure (time to maximum concentration, 8.4 vs 2.7 hours) and superior bioavailability (74.5% vs 36.6%).","Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18827074/),%,36.6,212241,DB00996,Gabapentin
,26352959,maximum concentration (Cmax),"The harmonic mean (±SD) maximum concentration (Cmax), time to maximum concentration (Tmax), and elimination half-life (tv2λZ) for gabapentin (11 mg/kg) were 6.17±0.83 μg/ml, 51.43±5.66 min, and 264.60±69.35 min, respectively.",PHARMACOKINETIC PROPERTIES OF A SINGLE ADMINISTRATION OF ORAL GABAPENTIN IN THE GREAT HORNED OWL (BUBO VIRGINIANUS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26352959/),[μg] / [ml],6.17,214992,DB00996,Gabapentin
,26352959,time to maximum concentration (Tmax),"The harmonic mean (±SD) maximum concentration (Cmax), time to maximum concentration (Tmax), and elimination half-life (tv2λZ) for gabapentin (11 mg/kg) were 6.17±0.83 μg/ml, 51.43±5.66 min, and 264.60±69.35 min, respectively.",PHARMACOKINETIC PROPERTIES OF A SINGLE ADMINISTRATION OF ORAL GABAPENTIN IN THE GREAT HORNED OWL (BUBO VIRGINIANUS). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26352959/),min,51.43,214993,DB00996,Gabapentin
,26352959,elimination half-life (tv2λZ),"The harmonic mean (±SD) maximum concentration (Cmax), time to maximum concentration (Tmax), and elimination half-life (tv2λZ) for gabapentin (11 mg/kg) were 6.17±0.83 μg/ml, 51.43±5.66 min, and 264.60±69.35 min, respectively.",PHARMACOKINETIC PROPERTIES OF A SINGLE ADMINISTRATION OF ORAL GABAPENTIN IN THE GREAT HORNED OWL (BUBO VIRGINIANUS). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26352959/),min,264.60,214994,DB00996,Gabapentin
,30212356,peak plasma concentration ( Cmax),"Respectively for the 15 mg/kg and 25 mg/kg dose, mean peak plasma concentration ( Cmax) was (mean ± pseudo SD) 13.23 ± 1.47 and 24.48 ± 5.81 μg/ml; mean time to peak plasma concentration ( Tmax) was 0.50 ± 0.24 and 0.56 ± 0.28 hr; mean area under the curve (AUC) was 76.0 ± 26.3 and 114.7 ± 27.5 hr·μg/ml; and mean terminal half-life ( T1/2) was 3.39 ± 0.90 and 4.46 ± 1.12 hr.",PHARMACOKINETICS OF ORAL GABAPENTIN IN CARIBBEAN FLAMINGOS ( PHOENICOPTERUS RUBER RUBER). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30212356/),[μg] / [ml],13.23,216965,DB00996,Gabapentin
,30212356,peak plasma concentration ( Cmax),"Respectively for the 15 mg/kg and 25 mg/kg dose, mean peak plasma concentration ( Cmax) was (mean ± pseudo SD) 13.23 ± 1.47 and 24.48 ± 5.81 μg/ml; mean time to peak plasma concentration ( Tmax) was 0.50 ± 0.24 and 0.56 ± 0.28 hr; mean area under the curve (AUC) was 76.0 ± 26.3 and 114.7 ± 27.5 hr·μg/ml; and mean terminal half-life ( T1/2) was 3.39 ± 0.90 and 4.46 ± 1.12 hr.",PHARMACOKINETICS OF ORAL GABAPENTIN IN CARIBBEAN FLAMINGOS ( PHOENICOPTERUS RUBER RUBER). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30212356/),[μg] / [ml],24.48,216966,DB00996,Gabapentin
,30212356,time to peak plasma concentration ( Tmax),"Respectively for the 15 mg/kg and 25 mg/kg dose, mean peak plasma concentration ( Cmax) was (mean ± pseudo SD) 13.23 ± 1.47 and 24.48 ± 5.81 μg/ml; mean time to peak plasma concentration ( Tmax) was 0.50 ± 0.24 and 0.56 ± 0.28 hr; mean area under the curve (AUC) was 76.0 ± 26.3 and 114.7 ± 27.5 hr·μg/ml; and mean terminal half-life ( T1/2) was 3.39 ± 0.90 and 4.46 ± 1.12 hr.",PHARMACOKINETICS OF ORAL GABAPENTIN IN CARIBBEAN FLAMINGOS ( PHOENICOPTERUS RUBER RUBER). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30212356/),h,0.50,216967,DB00996,Gabapentin
,30212356,time to peak plasma concentration ( Tmax),"Respectively for the 15 mg/kg and 25 mg/kg dose, mean peak plasma concentration ( Cmax) was (mean ± pseudo SD) 13.23 ± 1.47 and 24.48 ± 5.81 μg/ml; mean time to peak plasma concentration ( Tmax) was 0.50 ± 0.24 and 0.56 ± 0.28 hr; mean area under the curve (AUC) was 76.0 ± 26.3 and 114.7 ± 27.5 hr·μg/ml; and mean terminal half-life ( T1/2) was 3.39 ± 0.90 and 4.46 ± 1.12 hr.",PHARMACOKINETICS OF ORAL GABAPENTIN IN CARIBBEAN FLAMINGOS ( PHOENICOPTERUS RUBER RUBER). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30212356/),h,0.56,216968,DB00996,Gabapentin
,30212356,area under the curve (AUC),"Respectively for the 15 mg/kg and 25 mg/kg dose, mean peak plasma concentration ( Cmax) was (mean ± pseudo SD) 13.23 ± 1.47 and 24.48 ± 5.81 μg/ml; mean time to peak plasma concentration ( Tmax) was 0.50 ± 0.24 and 0.56 ± 0.28 hr; mean area under the curve (AUC) was 76.0 ± 26.3 and 114.7 ± 27.5 hr·μg/ml; and mean terminal half-life ( T1/2) was 3.39 ± 0.90 and 4.46 ± 1.12 hr.",PHARMACOKINETICS OF ORAL GABAPENTIN IN CARIBBEAN FLAMINGOS ( PHOENICOPTERUS RUBER RUBER). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30212356/),[h·μg] / [ml],76.0,216969,DB00996,Gabapentin
,30212356,area under the curve (AUC),"Respectively for the 15 mg/kg and 25 mg/kg dose, mean peak plasma concentration ( Cmax) was (mean ± pseudo SD) 13.23 ± 1.47 and 24.48 ± 5.81 μg/ml; mean time to peak plasma concentration ( Tmax) was 0.50 ± 0.24 and 0.56 ± 0.28 hr; mean area under the curve (AUC) was 76.0 ± 26.3 and 114.7 ± 27.5 hr·μg/ml; and mean terminal half-life ( T1/2) was 3.39 ± 0.90 and 4.46 ± 1.12 hr.",PHARMACOKINETICS OF ORAL GABAPENTIN IN CARIBBEAN FLAMINGOS ( PHOENICOPTERUS RUBER RUBER). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30212356/),[h·μg] / [ml],114.7,216970,DB00996,Gabapentin
,30212356,terminal half-life ( T1/2),"Respectively for the 15 mg/kg and 25 mg/kg dose, mean peak plasma concentration ( Cmax) was (mean ± pseudo SD) 13.23 ± 1.47 and 24.48 ± 5.81 μg/ml; mean time to peak plasma concentration ( Tmax) was 0.50 ± 0.24 and 0.56 ± 0.28 hr; mean area under the curve (AUC) was 76.0 ± 26.3 and 114.7 ± 27.5 hr·μg/ml; and mean terminal half-life ( T1/2) was 3.39 ± 0.90 and 4.46 ± 1.12 hr.",PHARMACOKINETICS OF ORAL GABAPENTIN IN CARIBBEAN FLAMINGOS ( PHOENICOPTERUS RUBER RUBER). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30212356/),h,3.39,216971,DB00996,Gabapentin
,30212356,terminal half-life ( T1/2),"Respectively for the 15 mg/kg and 25 mg/kg dose, mean peak plasma concentration ( Cmax) was (mean ± pseudo SD) 13.23 ± 1.47 and 24.48 ± 5.81 μg/ml; mean time to peak plasma concentration ( Tmax) was 0.50 ± 0.24 and 0.56 ± 0.28 hr; mean area under the curve (AUC) was 76.0 ± 26.3 and 114.7 ± 27.5 hr·μg/ml; and mean terminal half-life ( T1/2) was 3.39 ± 0.90 and 4.46 ± 1.12 hr.",PHARMACOKINETICS OF ORAL GABAPENTIN IN CARIBBEAN FLAMINGOS ( PHOENICOPTERUS RUBER RUBER). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30212356/),h,4.46,216972,DB00996,Gabapentin
,10863139,AUC,Study A: Overall mean (CV) of GBP AUC values was 34.1+/-24 ug/h per ml.,Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10863139/),[ug] / [h·ml],34.1,217292,DB00996,Gabapentin
,20738383,ED(50),"α-F-TMCD was active in the two pain models, and was found to be equipotent to gabapentin in the SNL model (ED(50) = 37 and 32 mg/kg, respectively).","Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20738383/),[mg] / [kg],37,224631,DB00996,Gabapentin
,20738383,ED(50),"α-F-TMCD was active in the two pain models, and was found to be equipotent to gabapentin in the SNL model (ED(50) = 37 and 32 mg/kg, respectively).","Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20738383/),[mg] / [kg],32,224632,DB00996,Gabapentin
,18201732,ED(50),"(R)-, (S)- and (R,S)-PID produced dose-related reversal of tactile allodynia with ED(50) values of 46, 48, 42 mg/kg, respectively.","Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201732/),[mg] / [kg],46,227608,DB00996,Gabapentin
,18201732,ED(50),"(R)-, (S)- and (R,S)-PID produced dose-related reversal of tactile allodynia with ED(50) values of 46, 48, 42 mg/kg, respectively.","Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201732/),[mg] / [kg],48,227609,DB00996,Gabapentin
,18201732,ED(50),"(R)-, (S)- and (R,S)-PID produced dose-related reversal of tactile allodynia with ED(50) values of 46, 48, 42 mg/kg, respectively.","Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201732/),[mg] / [kg],42,227610,DB00996,Gabapentin
,8827398,half-life,"When used as a monotherapy, topiramate is eliminated primarily in the urine in an unchanged form with a half-life of 20 to 30 hours; elimination is faster in patients receiving concurrent medication with enzyme-inducing anticonvulsants, in whom the extent of biotransformation becomes more prominent.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,20 to 30,232847,DB00996,Gabapentin
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,50 to 70,232848,DB00996,Gabapentin
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,25 to 35,232849,DB00996,Gabapentin
,8827398,half-life,"It is highly (96%) bound to plasma proteins and it is eliminated primarily by cytochrome P450 3A-mediated oxidation, with a half-life of about 7 hours in healthy volunteers.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,7,232850,DB00996,Gabapentin
,16190933,plasma concentration ratios,"The umbilical cord/maternal plasma concentration ratios ranged from 1.3 to 2.1 (mean, 1.7).","Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16190933/),,1.7,238859,DB00996,Gabapentin
,16190933,half-life,GBP plasma concentrations in the neonates declined with an estimated half-life of 14 h.,"Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16190933/),h,14,238860,DB00996,Gabapentin
,16190933,milk/maternal plasma concentration ratio,"The mean milk/maternal plasma concentration ratio was 1.0 (range, 0.7-1.3) from 2 weeks to 3 months.","Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16190933/),,1.0,238861,DB00996,Gabapentin
,20137764,bioavailability,"Mean (standard deviation) bioavailability (based on urinary recovery) of gabapentin from gabapentin enacarbil was 42.0 (6.1)% (fasted), 64.3 (13.2)% (low-fat meal), 64.9 (16.9)% (moderate-fat meal), and 76.1 (14.4)% (high-fat meal).",The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137764/),%,42.0,245625,DB00996,Gabapentin
,20137764,bioavailability,"Mean (standard deviation) bioavailability (based on urinary recovery) of gabapentin from gabapentin enacarbil was 42.0 (6.1)% (fasted), 64.3 (13.2)% (low-fat meal), 64.9 (16.9)% (moderate-fat meal), and 76.1 (14.4)% (high-fat meal).",The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137764/),%,64.3,245626,DB00996,Gabapentin
,20137764,bioavailability,"Mean (standard deviation) bioavailability (based on urinary recovery) of gabapentin from gabapentin enacarbil was 42.0 (6.1)% (fasted), 64.3 (13.2)% (low-fat meal), 64.9 (16.9)% (moderate-fat meal), and 76.1 (14.4)% (high-fat meal).",The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137764/),%,64.9,245627,DB00996,Gabapentin
,20137764,bioavailability,"Mean (standard deviation) bioavailability (based on urinary recovery) of gabapentin from gabapentin enacarbil was 42.0 (6.1)% (fasted), 64.3 (13.2)% (low-fat meal), 64.9 (16.9)% (moderate-fat meal), and 76.1 (14.4)% (high-fat meal).",The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137764/),%,76.1,245628,DB00996,Gabapentin
,28070716,CL,The GBP CL in elderly nursing home patients was 2.93 L/h.,Pharmacokinetics and Saturable Absorption of Gabapentin in Nursing Home Elderly Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28070716/),[l] / [h],2.93,260015,DB00996,Gabapentin
,9579927,half-life (t1/2),The GBP half-life (t1/2) for the 2 children after oral doses were 4.2 and 4.8 h.,Failure of absorption of gabapentin after rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579927/),h,4.2,262537,DB00996,Gabapentin
,9579927,half-life (t1/2),The GBP half-life (t1/2) for the 2 children after oral doses were 4.2 and 4.8 h.,Failure of absorption of gabapentin after rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579927/),h,4.8,262538,DB00996,Gabapentin
,26780452,V max,"The plasma/brain ECF concentration-time profiles of gabapentin were adequately described with a two-compartment plasma model with saturable intestinal absorption rate (K m = 44.1 mg/kg, V max = 41.9 mg/h∙kg) and dose-dependent oral bioavailability linked to brain ECF concentration through a transit compartment.",Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26780452/),[mg] / [h∙kg],41.9,263535,DB00996,Gabapentin
,26780452,EC 50,"Brain ECF concentration was directly linked to a sigmoid E max function describing reversal of hyperalgesia (EC 50, plasma = 16.7 μg/mL, EC 50, brain = 3.3 μg/mL).",Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26780452/),[μg] / [ml],16.7,263536,DB00996,Gabapentin
,26780452,EC 50,"Brain ECF concentration was directly linked to a sigmoid E max function describing reversal of hyperalgesia (EC 50, plasma = 16.7 μg/mL, EC 50, brain = 3.3 μg/mL).",Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26780452/),[μg] / [ml],3.3,263537,DB00996,Gabapentin
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB00996,Gabapentin
